---
document_datetime: 2023-09-21 20:44:14
document_pages: 58
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/vosevi-h-c-004350-x-0045-g-epar-assessment-report-variation_en.pdf
document_name: vosevi-h-c-004350-x-0045-g-epar-assessment-report-variation_en.pdf
version: success
processing_time: 48.8524214
conversion_datetime: 2025-12-23 05:19:15.359102
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

22 July 2021 EMA/480638/2021 Committee for Medicinal Products for Human Use (CHMP)

## CHMP assessment report on group of an extension of marketing authorisation and an extension of indication variation

Vosevi

International non-proprietary name: sofosbuvir / velpatasvir / voxilaprevir

Procedure No. EMEA/H/C/004350/X/0045/G

Official address

Domenico Scarlattilaan 6

Address for visits and deliveries

●

1083 HS Amsterdam

●

The Netherlands

Refer to www.ema.europa.eu/how-to-find-us

Send us a question

Go to www.ema.europa.eu/contact

Telephone

+31 (0)88 781 6000

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Administrative information

| Name of the medicinal product:         | Vosevi                                                                                                                                             |
|----------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| MAH:                                   | Gilead Sciences Ireland UC IDA Business & Technology Park Carrigtohill County Cork T45 DP77 IRELAND                                                |
| Active substance:                      | sofosbuvir / velpatasvir / voxilaprevir                                                                                                            |
| International Non-proprietary Name:    | sofosbuvir / velpatasvir / voxilaprevir                                                                                                            |
| Pharmaco-therapeutic group (ATC Code): | Antivirals for systemic use; Direct-acting antivirals (J05AP56)                                                                                    |
| Therapeutic indication(s):             | Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg |
| Pharmaceutical form(s):                | Film-coated tablet                                                                                                                                 |
| Strength(s):                           | 400 mg / 100 mg / 100 mg 200 mg / 50 mg / 50 mg                                                                                                    |
| Route(s) of administration:            | Oral use                                                                                                                                           |
| Packaging:                             | bottle (HDPE)                                                                                                                                      |
| Package size(s):                       | 28 tablets                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure ..............................................7                              |                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| 1.1. Submission of the dossier....................................................................................      | 7                                                                                                    |
| 1.2. Steps taken for the assessment of the product                                                                      | ....................................................... 8                                            |
| 2. Scientific discussion ................................................................................9              |                                                                                                      |
| 2.1. Problem statement.............................................................................................     | 9                                                                                                    |
| 2.1.1. Disease or condition.........................................................................................    | 9                                                                                                    |
| 2.1.2. Epidemiology                                                                                                     | .................................................................................................. 9 |
| 2.1.3. Aetiology and pathogenesis...............................................................................        | 9                                                                                                    |
| 2.1.4. Clinical presentation and diagnosis...................................................................           | 10                                                                                                   |
| 2.1.5. Management.................................................................................................      | 10                                                                                                   |
| 2.2. Quality aspects ................................................................................................   | 11                                                                                                   |
| 2.2.1. Introduction                                                                                                     | ................................................................................................. 11 |
| 2.2.2. Active Substance...........................................................................................      | 11                                                                                                   |
| 2.2.3. Finished Medicinal Product ..............................................................................        | 12                                                                                                   |
| 2.2.4. Discussion on chemical, pharmaceutical and biological aspects.............................                       | 15                                                                                                   |
| 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects                                               | ..................... 15                                                                             |
| 2.2.6. Recommendations for future quality development                                                                   | .............................................. 15                                                    |
| 2.3. Non-clinical aspects..........................................................................................     | 15                                                                                                   |
| 2.3.1. Ecotoxicity/environmental risk assessment........................................................                | 15                                                                                                   |
| 2.3.2. Discussion on non-clinical aspects....................................................................           | 16                                                                                                   |
| 2.3.3. Conclusion on non-clinical aspects ...................................................................           | 16                                                                                                   |
| 2.4. Clinical aspects ................................................................................................  | 16                                                                                                   |
| 2.4.1. Introduction                                                                                                     | ................................................................................................. 16 |
| 2.4.2. Pharmacokinetics ..........................................................................................      | 17                                                                                                   |
| 2.4.3. Discussion on clinical pharmacology .................................................................            | 26                                                                                                   |
| 2.4.4. Conclusions on clinical pharmacology ...............................................................             | 26                                                                                                   |
| 2.5. Clinical efficacy ................................................................................................ | 26                                                                                                   |
| 2.5.1. Dose response studies and main clinical studies.................................................                 | 26                                                                                                   |
| 2.5.2. Discussion on clinical efficacy ..........................................................................       | 41                                                                                                   |
| 2.5.3. Conclusions on the clinical efficacy...................................................................          | 41                                                                                                   |
| 2.6. Clinical safety .................................................................................................. | 41                                                                                                   |
| 2.6.1. Discussion on clinical safety ............................................................................       | 48                                                                                                   |
| 2.6.2. Conclusions on the clinical safety.....................................................................          | 49                                                                                                   |
| 2.7. Risk Management Plan......................................................................................         | 49                                                                                                   |
| 2.8. Pharmacovigilance............................................................................................      | 53                                                                                                   |
| 2.9. Product information..........................................................................................      | 53                                                                                                   |
| 2.9.1. User consultation...........................................................................................     | 53 53                                                                                                |
| 2.9.2. Additional monitoring.....................................................................................       |                                                                                                      |
| 3. Benefit-Risk Balance..............................................................................54                 |                                                                                                      |
| ......................................................................................... 3.1.1. Disease or             | condition....................................................................................... 54  |
| 3.1. Therapeutic Context                                                                                                | 54                                                                                                   |
| 3.1.2. Available therapies and unmet medical need                                                                       | ..................................................... 54                                             |

<div style=\"page-break-after: always\"></div>

| 3.1.3. Main clinical studies .......................................................................................   | 54   |
|------------------------------------------------------------------------------------------------------------------------|------|
| 3.2. Favourable effects............................................................................................    | 55   |
| 3.3. Uncertainties and limitations about favourable effects ...........................................                | 55   |
| 3.4. Unfavourable effects.........................................................................................     | 55   |
| 3.5. Uncertainties and limitations about unfavourable effects ........................................                 | 55   |
| 3.6. Effects Table ................................................................................................... | 56   |
| 3.7. Benefit-risk assessment and discussion ...............................................................            | 56   |
| 3.7.1. Importance of favourable and unfavourable effects ............................................                  | 56   |
| 3.7.2. Balance of benefits and risks...........................................................................        | 56   |
| 3.8. Conclusions.....................................................................................................  | 57   |
| 4. Recommendations.................................................................................57                  |      |

<div style=\"page-break-after: always\"></div>

## List of abbreviations

AE

adverse event

ALT

alanine aminotransferase

APRI

aspartate aminotransferase to platelet ratio index

AST

aspartate aminotransferase

BMI

body mass index

CFU

Colony Forming Units

CSR

clinical study report

CTX

C-type collagen sequence

DAA

direct-acting antiviral

eGFR

estimated glomerular filtration rate

EU

European Union

FAS

Full Analysis Set

FDC

fixed-dose combination

FIB-4

Fibrosis-4

Gilead

Gilead Sciences

GT

genotype

HCV

hepatitis C virus

HDPE

High Density Polyethylene

HPLC

High performance liquid chromatography

ICH

International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use

IL28B

IL28B gene

LDV

ledipasvir (GS-5885)

LLOQ

lower limit of quantitation

MedDRA

Medical Dictionary for Regulatory Activities

N

number of subjects

NI

nucleoside inhibitor

NLT

Not less than

NMT

Not more than

NS

nonstructural protein (3, 5A, 5B)

P1NP

procollagen type 1 N-terminal propeptide

Peg-IFN

pegylated interferon

Ph. Eur.

European Pharmacopoeia

PI

protease inhibitor

PK

pharmacokinetic(s)

Q1

first quartile

Q3

third quartile

RAV

resistance-associated variant

RBV

ribavirin

RNA

ribonucleic acid

SAE

serious adverse event

SAP

statistical analysis plan

SD

standard deviation

SDD

Spray-dried dispersion

SmPC

Summary of Product Characteristics

SOC

system organ class

SOF

sofosbuvir

SOF/VEL/VOX

sofosbuvir/velpatasvir/voxilaprevir (coformulated; Vosevi®)

<div style=\"page-break-after: always\"></div>

| SVR    | sustained virologic response                   |
|--------|------------------------------------------------|
| TSE    | Transmissible Spongiform Encephalopathy        |
| uHPLC  | ultra-high-performance liquid chromatography   |
| ULN    | upper limit of normal                          |
| US     | United States                                  |
| USP    | United States Pharmacopoeia                    |
| USP/NF | United States Pharmacopoeia/National Formulary |
| UV     | Ultraviolet                                    |
| VEL    | velpatasvir (GS-5816)                          |
| VOX    | voxilaprevir                                   |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Submission of the dossier

Gilead Sciences Ireland UC submitted on 14 September 2020 a group of variation(s) consisting of an extension of the marketing authorisation and the following variation(s):

| Variation(s) requested   | Variation(s) requested                                                                                                         | Type   |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------|--------|
| C.I.6.a                  | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | II     |

Extension application to introduce a new strength (200 mg /50 mg /50 mg film-coated tablets). The new presentation is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older or weighing at least 30 kg, who cannot swallow the higher strength tablet. In addition, the MAH took the opportunity to implement minor editorial updates in module 3.2.P.

The extension application is grouped with a type II variation (C.I.6.a) to include paediatric use in patients aged 12 years and older or weighing at least 30 kg to the existing presentation. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.2) is updated in accordance.

## The legal basis for this application refers to:

Article 7.2 of Commission Regulation (EC) No 1234/2008 - Group of variations

## Information on Paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0006/2020 on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the PIP P/0006/2020 was completed.

The PDCO issued an opinion on compliance for the PIP P/0006/2020.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

The MAH did not seek Scientific advice at the CHMP.

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur appointed by the CHMP was:

Rapporteur: Filip Josephson

| The application was received by the EMA on                                                                                                                                             | 14 September 2020   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|
| The procedure started on                                                                                                                                                               | 29 October 2020     |
| The Rapporteur's first Assessment Report was circulated to all CHMP members on                                                                                                         | 19 January 2021     |
| The PRAC Rapporteur's first Assessment Report was circulated to all PRAC members on                                                                                                    | 26 January 2021     |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 11 February 2021    |
| The CHMP agreed on the consolidated List of Questions to be sent to the MAH during the meeting on                                                                                      | 25 February 2021    |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                          | 19 March 2021       |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Questions to all CHMP members on                                                                | 20 April 2021       |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 6 May 2021          |
| The CHMP agreed on the consolidated List of Outstanding Issues to be sent to the MAH during the meeting on                                                                             | 20 May 2021         |
| The MAH submitted the responses to the CHMP consolidated List of Questions on                                                                                                          | 22 June 2021        |
| The Pharmacokinetics Working Party experts were convened to address questions raised by the CHMP                                                                                       | 1 July 2021         |
| The Rapporteurs circulated the Joint Assessment Report on the responses to the List of Outstanding Issues to all CHMP members on                                                       | 07 July 2021        |
| The PRAC agreed on the PRAC Assessment Overview and Advice to CHMP during the meeting on                                                                                               | 08 July 2021        |
| The Quality Working Party experts were convened to address questions raised by the CHMP                                                                                                | 14 July 2021        |
| The CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a marketing authorisation to Vosevi on | 22 July 2021        |

<div style=\"page-break-after: always\"></div>

## 2. Scientific discussion

## 2.1. Problem statement

The natural history of chronic HCV infection in children is relatively benign. Most children are asymptomatic or have mild nonspecific symptoms; however, cirrhosis has been reported in approximately 1% to 2% of adolescents, and advanced liver disease and decompensated cirrhosis have been reported in children as young as 3 years of age. Disease progression also may occur many years after the initial infection.

Other direct-acting antivirals (DAA) options in children: Sovaldi (SOF) and Harvoni (ledipasvir [LDV]/SOF) have been approved for the treatment of DAA-naive paediatric patients 3 to &lt; 18 years old in the European Union (EU). Epclusa (an FDC of SOF and VEL; SOF/VEL) has also been approved for the treatment of DAA-naive paediatric patients 6 to &lt; 18 years old in EU.

It is anticipated that as more paediatric patients are treated for HCV with DAA-based therapies, the number of patients who fail those treatments will increase. However, retreatment options are limited for patients who fail DAA treatment, particularly regimens that include an NS5A inhibitor and/or NS5B inhibitor.

## 2.1.1. Disease or condition

Treatment of chronic HCV infection in patients aged 12 years and older.

## 2.1.2. Epidemiology

Around 71 million individuals worldwide are chronically infected with HCV. The global prevalence in 2018 of HCV infection in children aged 0 to 18 years has been estimated to be 0.13%, or 3.26 million children; over half (1.83 million) were aged 12 to 18 years old. Prevalence also varies by geographic location, with prevalence rates estimated to be 0.04% in Western Europe and 0.06% in the United States (US) compared with rates of 0.40% in Eastern Europe and up to 1.74% in Mongolia. Approximately 50% of the children with HCV infection were estimated to be living in Pakistan, China, India, and Nigeria.

## 2.1.3. Aetiology and pathogenesis

The HCV has significant genetic (RNA sequence) variability; 8 major genotypes have been identified: genotypes 1 and 3 are the most prevalent globally (46% and 30%, respectively) while genotypes 2, 4, and 6 represent approximately 23% of cases, genotypes 5 and 7 plus recently 8 comprise &lt; 1%. There is a regional predominance of certain genotypes.

Hepatitis C is a blood-borne virus. Most infections occur as a result of sharing needles or other equipment to inject illicit drugs. HCV may or may not cause a short-term illness with features of acute hepatitis at the time of acquisition. About 70%-85% of infected persons do not clear the virus and therefore HCV becomes a long-term chronic infection. Chronic HCV infection is a serious disease that, left untreated, can be fatal due to decompensated liver cirrhosis and/or hepatocellular carcinoma (HCC). Globally, 27% of all cirrhosis and 25% of all HCC are attributable to HCV infection. In addition, persons with chronic HCV infection may develop extra-hepatic manifestations, such as cryoglobulinaemia, renal disease and porphyria cutanea tarda.

<div style=\"page-break-after: always\"></div>

## 2.1.4. Clinical presentation and diagnosis

The natural history of chronic HCV infection in children is generally similar to that in adults, although HCV infection in children is typically relatively mild (Squires 2017). Most children chronically infected with HCV are asymptomatic or have mild, nonspecific symptoms. Clinical symptoms are present in approximately 20% of children in the first 4 years of life, with hepatomegaly being the most frequent sign (10%). Many, but not all, perinatally-infected children will have intermittently or persistently abnormal alanine aminotransferase (ALT) or aspartate aminotransferase levels, particularly in the first 2 years of life. In children with vertical HCV infection who have undergone liver biopsy, the histological spectrum is usually mild, although severe liver disease is encountered {Mohan 2010}. Despite the overall more favourable prognosis compared with adults, approximately 4% to 6% of children with chronic HCV infection have evidence of advanced fibrosis or cirrhosis and some children eventually require liver transplantation as a consequence of HCV infection (Hu 2010), (Wirth 2012). In addition, HCV infection has been reported to negatively affect both the health-related quality of life and cognitive functioning of paediatric patients (Nydegger 2008), (Rodrigue 2009), (Abu Faddan 2015), (Annunziato 2017).

## 2.1.5. Management

Curing chronic HCV infection is associated with more than 70% reduction in the risk of HCC and 90% reduction in the risk of liver related mortality and liver transplantation.

HCV treatment has been transformed by the development and approval of DAAs that target viral proteins and cellular processes essential to HCV replication and which have activity against multiple HCV genotypes. Several of these agents with different viral targets are now available in fixed-dose combinations (FDC) form for once daily dosing for 12 weeks and have been associated with &gt;90% cure rates.

For patients who fail DAA only treatment with regimens that include an NS5A inhibitor the retreatment options are limited. However, SOF/VEL/VOX is recommended for such patients according to the current HCV treatment guidelines from the American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) and European Association for the Study of the Liver (EASL).

The high success rates with DAA regimens in adults with chronic HCV infection are increasingly being replicated in the paediatric population. Interferon and ribavirin exert general and paediatric-specific toxicities (e.g., temporary growth impairment) that do not occur with DAA regimens.

## About the product

Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir) is a fixed-dose combination product currently indicated for the treatment of patients with chronic HCV infection. Sofosbuvir is a nucleotide analogue non-structural protein NS5B polymerase inhibitor approved in EU for use in combination with other medicinal products for the treatment of chronic hepatitis C virus infection in adults and paediatric patients aged 3 years and above. Velpatasvir is an HCV NS5A inhibitor approved in EU for use in combination with SOF for the treatment of chronic hepatitis C virus infection in patients aged 6 years and older. Voxilaprevir is a novel pangenotypic HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity.

<div style=\"page-break-after: always\"></div>

## Type of Application and aspects on development

There was no scientific advice given from Committee for Medicinal Products for Human Use (CHMP) regarding the development of the new low dose tablet 200/50/50 mg and therapeutic indication for Vosevi in adolescents from 12 years of age and older.

Overall, the design of the paediatric study GS-US-367-1175 was in line with the outline in the CHMP guidance. Efficacy and safety is extrapolated from adults to adolescents based on the principle of comparable systemic exposure (PK bridge) in line with the 2016 EMA draft 'Guidelines on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis'.

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included an EMA Decision P/0006/2020 on the agreement of a paediatric investigation plan (PIP).  The PIP included a waiver for children less than 12 years old on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments in younger children. At the time of submission of the application, the PIP P/0006/2020 was completed.

## 2.2. Quality aspects

## 2.2.1. Introduction

The finished product is presented as film-coated tablets containing 200 mg sofosbuvir, 50 mg velpatasvir and 50 mg voxilaprevir as active substances. This presentation is newly introduced with this line extension (to the already approved film-coated tablets containing 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir) for use in paediatric patients aged 12 years and older OR weighing at least 30 kg.

Other ingredients are:

Tablet core: colloidal anhydrous silica, copovidone, croscarmellose sodium (E468), lactose monohydrate, magnesium stearate and microcrystalline cellulose (E460).

Film-coating: iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), macrogol (E1521), polyvinyl alcohol (E1203), talc (E553b), titanium dioxide (E171).

The product is available in HDPE bottles with a polypropylene child-resistant closure with polyester coil and a silica gel desiccant as described in section 6.5 of the SmPC.

## 2.2.2. Active Substance

## General information

The active substances sofosbuvir, velpatasvir and voxilaprevir are the same as for the already authorised Vosevi 400 mg sofosbuvir, 100 mg velpatasvir and 100 mg voxilaprevir film-coated tablets. No new information on the active substances has been provided within this line extension application.

<div style=\"page-break-after: always\"></div>

## 2.2.3. Finished Medicinal Product

## Description of the product and Pharmaceutical development

The medicinal product is an immediate release film-coated tablet which contains a fixed dose combination of three active substances. The 200 mg sofosbuvir/ 50 mg velpatasvir/ 50 mg voxilaprevir tablet is presented as a beige, oval-shaped tablet debossed with 'GSI' on one side and 'SVV' on the other side.

Other ingredients are:

- Tablet core: colloidal anhydrous silica, copovidone, croscarmellose sodium (E468), lactose monohydrate, magnesium stearate and microcrystalline cellulose (E460).
- Film-coating: iron oxide black (E172), iron oxide red (E172), iron oxide yellow (E172), macrogol (E1521), polyvinyl alcohol (E1203), talc (E553b), titanium dioxide (E171).

The purpose of formulation development was to develop a reduced-strength tablet suitable for use in the paediatric population unable to swallow the approved 400 mg/ 100 mg/ 100 mg strength tablet.

The qualitative composition of the lower strengths 200 mg/ 50 mg/ 50 mg tablets is identical to the approved 400 mg/ 100 mg/ 100 mg tablets. The two tablet strengths are differentiated by tablet size, shape, and debossing.

All excipients are well known pharmaceutical ingredients and their quality is compliant with Ph. Eur standards, except for the film coating material, Opadry II beige, which is tested according to an inhouse standard and the colourant, iron oxide, contained in Opadry II beige, which complies with EU regulations. There are no novel excipients used in the finished product formulation. No new information related to excipients was presented with this line extension. The list of excipients is included in section 6.1 of the SmPC.

The formulation used during clinical studies is the same as that intended for marketing.

The 200 mg/ 50 mg/ 50 mg and 400 mg/ 100 mg/ 100 mg strength tablets are manufactured from a common blend and the manufacturing process used is the same as for the approved higher-strength tablets.

For the new 200mg/ 50mg/ 50mg lower-strength tablet, no in vivo data were presented, and the applicant sought a biowaiver of strength based on in vitro dissolution data. The justification for the request for biowaiver of strength as presented in the application was initially judged to be not sufficient and a Major Objection was raised during the procedure. Additional dissolution data were requested at three different pH without the use of surfactant. In response, the applicant presented dissolution profiles generated for sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) tablets, 400/100/100 mg and 200/50/50 mg (three batches of each strength). The dissolution profiles were obtained at the same dose of 400 mg of SOF, 100 mg of VEL, and 100 mg of VOX by comparing one SOF/VEL/VOX 400/100/100 mg tablet per vessel with two SOF/VEL/VOX 200/50/50 mg tablets per vessel. Dissolution profiles were also presented using the conditions of the approved dissolution method.

In summary, the CHMP concluded that the waiver for the additional strength is considered acceptable because of the similarity in dissolution at various pHs and of the QC method. Based on the available data and additional expert consultation, the CHMP concluded that the data presented was sufficient to resolve the Major Objection and to justify the biowaiver of strength for the new lower strength tablet.

<div style=\"page-break-after: always\"></div>

The primary packaging is similar for the 200 mg/ 50 mg/ 50 mg tablets and for the approved 400 mg/ 100 mg/ 100 mg tablets and differs only in the bottle size (60 ml rather than 100 ml bottle size). The primary packaging is a high-density polyethylene (HDPE) bottle with a polypropylene child-resistant closure with polyester coil and a silica gel desiccant. The material complies with Ph. Eur. and EC requirements

## Manufacture of the product and process controls

The manufacturing process for the new Vosevi film-coated tablets 200 mg/ 50 mg/ 50 mg is similar to the one used for the approved 400 mg/ 100 mg/ 100 mg tablets, except for the differences introduced by tablet size and shape, and scale of the processing equipment. The manufacturing process of the finished product consists of three stages: manufacture of the finished product intermediates velpatasvir spray-dried dispersion (VEL SDD) and voxilaprevir spray-dried dispersion (VOX SDD), and manufacture of the film-coated tablets.

VEL SDD and VOX SDD are finished product intermediates with separate specifications and shelf life. The manufacturing and control of these intermediates was approved with the initial application and subsequent variations and no changes were introduced as part of this line extension.

The manufacturing process of the film-coated tablets consists of the following main steps: powder processing (dispensing, blending, and dry granulation) of sofosbuvir, VEL SDD, VOX SDD, and excipients to yield the final powder blend for compression; tablet compression to yield tablet cores; film coating of tablet cores to yield film coated tablets, and primary packaging of film-coated tablets.

The process is considered to be a standard manufacturing process.

The overall control strategy, process parameters and in-process controls are adequate in view of the available development data and in view of the standard nature of the manufacturing process.

The robustness of the process has been demonstrated during development by the manufacture of representative batches. Process validation will be performed prior to commercial distribution of the product. An acceptable process validation scheme has been presented.

## Product specification

The finished product specifications include appropriate tests for this kind of dosage form including appearance (visual), identification (HPLC, UV), water content (Ph. Eur.), strength (assay, UPLC), degradation products (UPLC), uniformity of dosage units (Ph. Eur.), dissolution (Ph. Eur., UPLC) and microbiological examination (Ph. Eur.).

The specification for the new 200 mg/ 50 mg/ 50 mg tablets utilises the same tests and acceptance limits as approved for the 400 mg/ 100 mg/ 100 mg tablets.

The analytical procedures developed for the 400 mg/ 100 mg/ 100 mg strength tablets are used for testing of the 200 mg/ 50 mg/ 50 mg strength tablets. Except for the method for dissolution, sample preparation was proportionally scaled for the 200mg/ 50mg/ 50mg strength tablets.

The analytical methods used have been adequately described and appropriately validated in accordance with the ICH guidelines.

The potential presence of elemental impurities in the finished product has been assessed on a riskbased approach in line with the ICH Q3D Guideline for Elemental Impurities. Based on the risk assessment and the presented batch data it can be concluded that it is not necessary to include any

<div style=\"page-break-after: always\"></div>

elemental impurity controls in the finished product specification. The information on the control of elemental impurities is satisfactory.

A risk evaluation concerning the presence of nitrosamine impurities in the finished product has been performed considering all suspected and actual root causes in line with the 'Questions and answers for marketing authorisation holders/applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products' (EMA/409815/2020) and the 'Assessment report- Procedure under Article 5(3) of Regulation EC (No) 726/2004- Nitrosamine impurities in human medicinal products' (EMA/369136/2020). Based on the information provided it is accepted that no risk was identified on the possible presence of nitrosamine impurities in the active substance or the related finished product. Therefore, no additional control measures are deemed necessary.

Batch analysis results are provided for four production-scale batches confirming the consistency of the manufacturing process and its ability to manufacture to the intended product specification.

No new information on reference standards has been presented with this line extension application.

## Stability of the product

Stability data from three production scale batches of finished product stored for up to 12 months under long term conditions (30 ºC / 75% RH) and for up to 6 months under accelerated conditions (40 ºC / 75% RH) according to the ICH guidelines were provided. The batches of medicinal product are representative of those proposed for marketing and were packed in the primary packaging proposed for marketing. The analytical procedures used are stability indicating. No significant changes have been observed.

Manufacture of the new 200 mg/ 50 mg/ 50 mg tablets is from a powder blend common with the approved 400 mg/ 100 mg/ 100 mg tablets, for which a shelf life of 48 months is approved. The 400 mg/ 100 mg/ 100 mg tablets showed little or no change in all quality attributes after storage for up to 48 months at 30 ºC / 75% RH. It was observed that the stability data at accelerated storage conditions are comparable for the 200 mg/ 50 mg/ 50 mg tablets and the 400 mg/ 100 mg/ 100 mg tablets.

The date of tablet manufacture is defined as the date when VEL SDD, VOX SDD and sofosbuvir are combined with the excipients in tablet manufacture. Separate shelf-lives and definitions for the date of manufacture have been approved for VEL SDD and VOX SDD as part of the approval of the 400 mg/ 100 mg/ 100 mg strength tablet marketing authorisation.

Considering the supporting data from the approved 400 mg/ 100 mg/ 100 mg tablets, extrapolating the results from 12 months of stability data at long-term storage conditions and 6 months stability data at the accelerated storage conditions to support the proposed shelf-life and storage conditions of Vosevi 200 mg/ 50 mg/ 50 mg film-coated tablets, can be accepted.

Based on available stability data, the proposed shelf-life of 48 months and with no special storage conditions as stated in the SmPC (section 6.3) is acceptable. The tablets should be stored in the original package (bottle) in order to protect from moisture and this is indicated in section 6.4 of the SmPC.

## Adventitious agents

It is confirmed that the lactose is produced from milk from healthy animals in the same condition as those used to collect milk for human consumption and that the lactose has been prepared without the

<div style=\"page-break-after: always\"></div>

use of ruminant material other than calf rennet according to the Note for Guidance on Minimising the Risk of Transmitting Animal Spongiform Encephalopathy Agents Via Human and veterinary medicinal products.

## 2.2.4. Discussion on chemical, pharmaceutical and biological aspects

Information on development, manufacture and control of the active substance and finished product has been presented in a satisfactory manner.

During the procedure, a Major Objection was raised in relation to the justification for the request for biowaiver of strength and comparative dissolution profiles generated without the use of surfactant were requested. The additional data provided by the applicant was considered sufficient to resolve the Major Objection and justify the biowaiver of strength.

The results of tests carried out indicate consistency and uniformity of important product quality characteristics, and these in turn lead to the conclusion that the product should have a satisfactory and uniform performance in clinical use.

## 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects

The quality of this product is considered to be acceptable when used in accordance with the conditions defined in the SmPC. Physicochemical and biological aspects relevant to the uniform clinical performance of the product have been investigated and are controlled in a satisfactory way.

## 2.2.6. Recommendations for future quality development

Not applicable.

## 2.3. Non-clinical aspects

No new non-clinical studies have been submitted for this procedure.

## 2.3.1. Ecotoxicity/environmental risk assessment

The EMA guideline on the ERA states that 'the evaluation of the environmental impact should be made if there is an increase in the environmental exposure, e.g. a new indication may result in a significant increase in the extent of the use'. The prior ERAs for both SOF and VEL predicted environmental concentrations were estimated based on forecasted sales figures provided by the applicant. These forecasts covered the period of 2015 - 2024 for SOF and 2018 - 2024 for VEL and included a reserve/ margin of error that is higher than the small increase in sales that may occur due to the proposed line extension. For VOX, 100% prevalence based on the highest HCV prevalence observed in the European Union (EU) was applied to determine the predicted environmental concentration (PEC) (Italy - 5.2%). Therefore, it can be considered that the sales forecasts and use of prevalence data employed in the previous ERA accounted for the potential sales increase due to the proposed line extension. Hence the estimated PECs are still conservative and no update to the assessment is necessary. As detailed in the ERAs for SOF, VEL and VOX, Risk Quotient (RQ) values for SOF (as GS-331007), VEL, and VOX are less than 1 (highest RQ for SOF = 1.26x10 -4 , VEL= 1.08x10 -3 , and VOX = 6.26x10 -3 ) for compartments such as sewage treatment plant, surface water, groundwater, and sediment. An increase in Vosevi sales of greater than 160 times would be required to produce an unacceptable risk. This line extension

<div style=\"page-break-after: always\"></div>

grouped with an extension of indication is not expected to significantly increase sales continuing the low RQs.

## 2.3.2. Discussion on non-clinical aspects

No new non-clinical studies, including juvenile toxicity, have been submitted in support of the current application for use of Vosevi in adolescents 12 - &lt;18 years. This was considered acceptable by the CHMP as the non-clinical data safety data submitted in support of the original Vosevi marketing authorization application did not reveal any hazards specific for adolescents and agrees with the Vosevi paediatric investigation plan (PIP) as stated in the Paediatric Committee (PDCO) decision document, EMEA-001822-PIP01-15. In addition, adverse reactions by Vosevi in patients 12 years and older was studied for 8 weeks in a Phase-2 open-label clinical trial. The observed adverse reactions in this study comprising adolescents were consistent with those observed in clinical studies with Vosevi in adults.

No update of the ERA was submitted in support of the current extension of indication application. This is accepted as the existing ERAs for SOF, VEL, and VOX are considered applicable to this application.

## 2.3.3. Conclusion on non-clinical aspects

There are no issues with the dossier from a non-clinical perspective.

## 2.4. Clinical aspects

## 2.4.1. Introduction

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies

Table 1: Clinical Study Included in the Update to the SOF/VEL/VOX Marketing Application for Paediatric Subjects (12 to &lt; 18 years old)

<div style=\"page-break-after: always\"></div>

| Study Number   | Study Design              | Subject Population                                                                                | Treatment Regimena                                       | Nb                                                                      | Location of Study Summary                      |
|----------------|---------------------------|---------------------------------------------------------------------------------------------------|----------------------------------------------------------|-------------------------------------------------------------------------|------------------------------------------------|
| GS-US-367-1175 | Phase 2. open-label study | Treatment-naiveand treatment-experienced subjects 12 to < 18 years old with chronic HCV infection | SOF/VEL/VOX 400/100/100mg orally once daily for 8 weeksd | 12to<18years:21 Genotype 1: 6 Genotype 2: 4 Genotype 3: 9 Genotype 4: 2 | CSR: GS-US-365-1175 CSR Narrative: Section 2.1 |

CSR=clinical study report;DAA=direct-acting antiviral;HCV=hepatitis Cvirus;SOF=sofosbuvir;VEL=velpatasvir: Vox=voxilaprevir

- a Selectionoftabletstrength(400/100/100-mgor200/50/50-mg tablets)wasbasedon a swallowability assessmentusing a placebo tablet at screening or baseline.Al1 subjects were able to swallow the 400/100/100-mg tablet.
- C A waiver for subjects 3 to &lt;12years old was granted by the European Medicines Agency,so this age group was not recruited.
- b N = number of subjects in the Full Analysis Set (ie. all enrolled subjects who received at least 1 dose of study drug).
- d All subjects were DAA-naive and none had compensated cirrhosis, so the 12-week study drug regimen was not used in this study.

## 2.4.2. Pharmacokinetics

## Relative bioavailability study

No relative bioavailability study was performed in order to investigate interchangeability of two tablets of the 200/50/50 mg strength and one tablet of the 400/100/100 mg strength. Based on the available data and the input from the QWP and PKWP, the CHMP concluded that a biowaiver for the lowerstrength was justified, as detailed in section 2.2.3 of the CHMP AR.

## PopPK analysis

The objective of the popPk analysis was to:

- update a joint model evaluating the PK of SOF, its primary circulating metabolite (GS-331007), and metabolite GS-566500 in HCV-infected pediatric subjects
- To update a VEL population PK model with additional pediatric data in HCV-infected pediatric subjects administered
- To develop a population PK model for evaluating the PK of VOX in HCV-infected pediatric subjects
- To estimate individual exposures of SOF, GS-331007, GS-566500, VEL, and VOX in the pediatric population

## SOF Joint PopPK Model

A total of 85 Subjects in Study GS-US-334-1112, 198 subjects in Study GS-US-337-1116, 179 subjects in Study GS-US-342-1143, and 15 subjects in Study GS-US-367-1175 had at least 1 concentration value for GS-331007 included in the PopPK analysis. Plasma concentrations of SOF, GS566500, and GS-331007 were best described by a joint 1-compartment (SOF and GS-566500) and a 2-compartment (GS-331007) model, including first-order absorption with zero-order input for SOF and an absorption lag time (ALAG) for both SOF and GS-331007, followed by first-order elimination. The model included the effect of WT (allometric exponents fixed to 0.75 and 1 for clearances and volumes, respectively) on apparent oral clearance of SOF (CLSOF), apparent volume of SOF (VSOF),  apparent

<div style=\"page-break-after: always\"></div>

oral clearance of GS-566500 (CL500),  apparent volume of GS-566500 (V500), apparent oral clearance of GS-331007 (CL007), and apparent volume of GS-331007 (Vc007). Additionally, the model included the separate effect of coadministration of LDV and VEL on relative fraction absorbed for SOF (F1) and co-administration of RBV(ribavirin) on apparent oral clearance ofGS-566500 (CL500) and apparent oral clearance of GS-331007 (CL007).The model also included the effect of age on CL500 and CL007 and sex on CL007.

Table 2: Summary of Parameters for final SOF joint PopPK Model for Paediatric subjects

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Parameter                 | Parameter Deseription                                     | Parameter Deseription                                     | Population Estimate   | Change from Typieal (96)   | IV (96)   |
|---------------------------|-----------------------------------------------------------|-----------------------------------------------------------|-----------------------|----------------------------|-----------|
| exp(e1)                   | Absorplion rate for SOF, ksor (l/h)                       | Absorplion rate for SOF, ksor (l/h)                       | 1.22                  |                            |           |
| mp(e2)                    | Abrorption rate for GS-566500, kuw (l/h)                  | Abrorption rate for GS-566500, kuw (l/h)                  | 0.286                 |                            |           |
| exp(83)                   | Abrerption rate for GS-331007, korr (l/h)                 | Abrerption rate for GS-331007, korr (l/h)                 | 0.022                 |                            |           |
| exp(04)                   | Apparent eral elernee af SoF, CLser (L h)                 | Apparent eral elernee af SoF, CLser (L h)                 | 318                   |                            |           |
| exp(04+0.75 x bg(WI42))   | Influence of WT on CL.o!                                  | Sth %ile ofWT                                             | 161                   | -49.4                      | 81        |
| exp(04+0.75 x bg(WI42))   | Influence of WT on CL.o!                                  | 95th %ileof WT                                            | 549                   | 72.9                       | 81        |
| exp(85)                   | Apparent central volume of SOF, Vser (L)                  | Apparent central volume of SOF, Vser (L)                  | 161                   |                            |           |
| mp(05+1x bg(WT/42)        | Influemee of WT on Vsor                                   | Sth Hie ofWT                                              | 65                    | -59.7                      | 210       |
| mp(05+1x bg(WT/42)        | Influemee of WT on Vsor                                   | 95th %ieof WT                                             | 335                   | 107.5                      | 210       |
| exp(66)                   | Apparent oral clearance of GS-566500.CLm(L/h)             | Without RBV                                               | 118                   |                            | 32        |
| exp(020)                  | Apparent oral clearance of GS-566500.CLm(L/h)             | Wih RBV                                                   | 1352                  |                            | 32        |
| p(66+0.75 x bg(WT/42)     | Influence of WTon CL.o                                    | Sth %ileof WT                                             | 425                   | -49.4                      |           |
| p(66+0.75 x bg(WT/42)     | Influence of WTon CL.o                                    | 95th %ile of WT                                           |                       | 72.9                       |           |
| exp(06+026 x leg(AGE/12)) | Infhuance of AGE on CLio                                  | Sth 9bile of AGE                                          | 1019                  | 21.1                       |           |
| exp(06+026 x leg(AGE/12)) | Infhuance of AGE on CLio                                  | 95th ile of AGE                                           | 792                   | -5.9                       |           |
| exp(em)                   | Apparent eenhal volmme of GS-566500, Ve (L)               | Apparent eenhal volmme of GS-566500, Ve (L)               | 1167                  |                            |           |
| exp(07+1 x bg(WT42))      | Influenee of WT en Vim                                    | Sth %ile of WT                                            | 470                   | -59.7                      |           |
| exp(07+1 x bg(WT42))      | Influenee of WT en Vim                                    | 95th %ileof WT                                            | 2421                  | 107.3                      |           |
| p(08)                     | Apparenl oral clearnce of GS-331007, CL.o(L.h)            | Female without RBV                                        | 167                   |                            | 28        |
| exp(021)                  | Apparenl oral clearnce of GS-331007, CL.o(L.h)            | Female with RBV                                           | 181                   | 8.2                        | 28        |
| exp(08) ×(1 + 625)        | Apparenl oral clearnce of GS-331007, CL.o(L.h)            | Male with LDV                                             | 184                   | 10.1                       | 28        |
| exp(08+0.75 x bg(WT42)    | Influenee of WT en CLwn                                   | Sth%ileofWT                                               | 85                    | -49.4                      |           |
| exp(08+0.75 x bg(WT42)    | Influenee of WT en CLwn                                   | 95th %ile of WT                                           | 289                   | 72.9                       |           |
| p(e8+624x lg(AGE/12))     | Influwnce of AGE on CL.r                                  | 5ih ile of AGE                                            | 205                   | 22.5                       |           |
| p(e8+624x lg(AGE/12))     | Influwnce of AGE on CL.r                                  | 95th %ile of AGE                                          | 157                   | -62                        |           |
| exp(e9)                   | Appurmt cantal volme of GS-331007, Vo- (L)                | Appurmt cantal volme of GS-331007, Vo- (L)                | 220                   |                            |           |
| exp(69 + 1 x bg(WT/42))   | Infloenea of WT on Vow                                    | Sth %ile of WT                                            | 89                    | -59.7                      |           |
| exp(69 + 1 x bg(WT/42))   | Infloenea of WT on Vow                                    | 95h ieof WT                                               | 457                   | 107.5                      |           |
| exp(e10)                  | Apparent intereompartmental clearnce of Gs-331007. Q (Lh) | Apparent intereompartmental clearnce of Gs-331007. Q (Lh) | 49                    |                            |           |
| exp(e11)                  | Apparent peripheral vohme of GS-331007, V,we (L)          | Apparent peripheral vohme of GS-331007, V,we (L)          | 1005                  |                            |           |
| cp(612)                   | Duralion of zero-order absorption for SOF, D1 (h)         | Duralion of zero-order absorption for SOF, D1 (h)         | 0.56                  |                            |           |
| Fixed                     |                                                           | SOF+RBV                                                   | 1                     |                            |           |

<div style=\"page-break-after: always\"></div>

| Parameter        | ParameterDescription                              | ParameterDescription                              |   Population Estimate | Change from Typical (%)   | IIV (%)   |
|------------------|---------------------------------------------------|---------------------------------------------------|-----------------------|---------------------------|-----------|
| 1 +014 [Fixed]   | Relative fraction absorbed for SOF F1             | LDV/SOFFDC                                        |                 1.77  |                           |           |
| 1+ 023           | Relative fraction absorbed for SOF F1             | SOF/VEL FDC                                       |                 2.52  |                           |           |
| 613 [Fixed]      | Relative fraction absorbed for GS-331007,F3       | Relative fraction absorbed for GS-331007,F3       |                 7.18  |                           |           |
| 615 [Fixed]      | Relative fraction absorbed for GS-566500, F2      | Relative fraction absorbed for GS-566500, F2      |                 5.32  |                           |           |
| exp(618)         | Absorption lag time for GS-331007, ALAG3 (h)      | Absorption lag time for GS-331007, ALAG3 (h)      |                 3     |                           |           |
| exp(622) [Fixed] | Absorption lag time for SOF, ALAG1 (h)            | Absorption lag time for SOF, ALAG1 (h)            |                 0.082 |                           |           |
| 619 × 100        | Proportional error SD for SOF (%)                 | Proportional error SD for SOF (%)                 |                92.7   |                           |           |
| 616×100          | Proportional error SD for GS-566500 (%)           | Proportional error SD for GS-566500 (%)           |                61.4   |                           |           |
| 617×100          | Proportional error SD for GS-331007 (%)           | Proportional error SD for GS-331007 (%)           |                30.4   |                           |           |
|                  | Elimination half-life SOF (h)                     | Elimination half-life SOF (h)                     |                 0.35  |                           |           |
|                  | Elimination half-life GS-556500                   | Elimination half-life GS-556500                   |                 0.96  |                           |           |
|                  | Elimination half-life GS-331007 (SOF + RBV) (h)   | Elimination half-life GS-331007 (SOF + RBV) (h)   |                18.2   |                           |           |
|                  | Elimination half-life GS-331007 (LDV/SOF FDC) (h) | Elimination half-life GS-331007 (LDV/SOF FDC) (h) |                18.6   |                           |           |
|                  | Elimination half-life GS-331007 (SOF/VEL FDC) (h) | Elimination half-life GS-331007 (SOF/VEL FDC) (h) |                18.6   |                           |           |
|                  | Eliminationhalf-lifeGS-331007(SOF/VEL/VOXFDC) (h) | Eliminationhalf-lifeGS-331007(SOF/VEL/VOXFDC) (h) |                18.6   |                           |           |

CV = coefficient of variation; FDC = fixed-dosed combination; IIV = interindividual variability; LDV = ledipasvir; OFV = objective function value; PK = phanmacokinetic; PopPK = population pharmacokinetic; RBV =ribavirin; RV = residual variability; SD = standard deviation; SOF = sofosbuvir; VEL = velpatasvir, VOX = voxilaprevir; WT = baseline body weight. Minimum 0FV = 91577.471.

6 = absolute value ofthe estimate; @ = standard deviation of between-subject variability; %ile = percentile; AGE = baseline age;

The 5th and 95th percentiles of WT are 16.9 and 87.1 kg, respectively; the 5th and 95th percentiles of age are 4 and 17 years, respectively.

Source:sof-rum046-gof-final-20200413.R

Prediction-corrected VPC simulations were performed as a validation of the final PopPK model. A total of 1000 replicates of the studies were simulated using the final PopPK model parameter estimates, the estimated subject-specific ETA, and the RV. The pcVPCs of SOF plasma concentration-time profiles and its metabolites are shown in Figure 1 below.

SOF

<!-- image -->

<div style=\"page-break-after: always\"></div>

## GS-566500

<!-- image -->

GS-331007

<!-- image -->

<div style=\"page-break-after: always\"></div>

BLQ=below the limit of quantitation;CI=confidence interval;DV=observed concentrations;LLOQ=lower limit of quantitation; pcVPC = prediction-corrected visual predictive check; PopPK = population pharmacokinetic; SOF = sofosbuvir; WT =baselinebody weight.

Subjects aged 3 to &lt; 6 years old were only in Studies GS-US-334-1112, GS-US-337-1116, and GS-US-342-1143. The pcVPC plots show the median (solid black lines) and spread (5th to 95th percentile, dashed black line) of the DV in all subjects. The red areaisthe95%CIof thesimulatedmedian,and theblue areais the95CIofthesimulated5th and95thpercentiles.pcVPCis stratified by age category for SOF (top 3 panels), GS-566500 (middle 3 panels), and GS-331007 (bottom 3 panels).For the LLOQpanels,open circles and blacksolid lines show the observedproportion of BLQsamples,whereas theblue areashows the 95% CI of the simulated BLQ samples.

Source:sof-run046-gof-final-20200413.R

Figure 1: Prediction-corrected VPC simulations of SOF plasma concentration-time profiles and its metabolites

## VEL popPK model

The PopPK data included 209 subjects from Study GS-US-342-1143 and 21 subjects from Study GSUS-367-1175. After all exclusions, a total of 179 subjects in Study GS-US-342-1143 and 15 subjects from Study GS-US-367-1175 had at least 1 measurable concentration value for VEL. The final pediatric VEL model was described by a 2-compartment model with sequential zero-/first-order absorption and first-order elimination, with interindividual variability (IIV) on CL/F, Vc/F, and ka. The effect of WT on CL/F and Vc/F was included using fixed allometric exponents of 0.75 and 1, respectively. VOX was found to affect VEL CL/F (24.4% reduction). No additional covariates were found to significantly affect VEL exposure.

Table 3: Summary of parameters for final VEL PopPK model for paediatric subjects

<!-- image -->

Prediction-corrected VPC simulations were performed as a validation of the final PopPK model. A total of 1000 replicates of the studies were simulated using the final PopPK model parameter estimates, the estimated subject-specific ETA, and the RV (residual variability). The pcVPC of VEL plasma concentration-time profiles stratified by age groups are shown in Figure 2 below.

Source: Vel-gof-final-run124-20200430.R

<div style=\"page-break-after: always\"></div>

Figure 2: pcVPC of the final VEL PopPK model stratified by age

<!-- image -->

## VOX PopPK Model

The PopPK data included 21 subjects from Study GS-US-367 -1175. After all exclusions, a total of 15 subjects in Study GS-US-367 -1175 had at least 1 measurable concentration value for VOX. The final pediatric VOX model was described by a 2-compartment model with sequential zero and first-order absorption and first-order elimination, with IIV on CL/F, Vc/F, ka, and D1. The effect of WT on CL/F and Vc/F was included using fixed allometric exponents of 0.75 and 1, respectively. No additional covariates were found to significantly affect VOX exposure.

Visual Predictive Check simulations were performed as a validation of the final PopPK model. A total of 1000 replicates of the studies were simulated using the final PopPK model parameter estimates, the estimated subject-specific ETA, and the RV. The VPC of VOX plasma concentration-time profiles is shown in Figure 3 below.

<div style=\"page-break-after: always\"></div>

<!-- image -->

Figure 3: VPC with observations of the final VOX paediatric PipPK Models for Low and High Wekght Range

## Paediatric exposure:

Population PK models derived exposures of SOF, GS-331007, VEL, and VOX using intensive and sparse PK samples from paediatric subjects 12 to &lt; 18 years old in Study GS-US-367-1175 were compared with historical data collected in the adult Phase 2/3 SOF/VEL/VOX clinical studies as presented in Table below.

Table 4: Summary of popPK-based SOF, GS-331007, VEL and VOX exposures in adolescent subjects compared with popPK-based exposures in the adult phase 2/3 SOF/VEL/VOX population (PK analysis set)

|           |                | Mean (%CV)                                                   | Mean (%CV)                                       | %GMR (90% CI)                                     |
|-----------|----------------|--------------------------------------------------------------|--------------------------------------------------|---------------------------------------------------|
| Analyte   | PK Parameter   | AdolescentSubjects SOF/VEL/VOX （400/100/100mg） 8Wecks (N=21) | Adult Phase 2/3 SOF/VEL/VOX Population (N =1595) | Adolescent Subjects vs Adult Phase 2/3 Population |
| SOF       | AUCuu (hng/mL) | 2474.8 (50.4)                                                | 1665.3 (30.1)                                    | 137.75(123.66, 153.45)                            |
| SOF       | Cmx (ng/mL)    | 1304.7 (69.9)                                                | 677.9 (35.4)                                     | 162.64 (138.53,190.94)                            |
| GS-331007 | AUC (hong/mL)  | 14,890.2 (21.0)                                              | 12,834.1 (29.0)                                  | 118.49 (107.02, 131.19)                           |
| GS-331007 | Cmx (ng/mL)    | 1278.1 (16.1)                                                | 744.3 (28.3)                                     | 176.55 (158.98, 196.06)                           |
| VEL       | AUC (hng/mL)   | 6773.0 (35.0)                                                | 4041.1 (48.6)                                    | 176.53 (147.25, 211.63)                           |
| VEL       | Cmx (ng/mL)    | 621.8 (37.6)                                                 | 311.1 (56.1)                                     | 215.54 (174.79, 265.80)                           |
| VEL       | C (ng/mL)      | 92.0 (49.6)                                                  | 51.2 (64.7)                                      | 188.51 (154.18, 230.49)                           |
| Vox       | AUCu (h·ng/mL) | 2205.8 (63.0)                                                | 2577.2 (73.7)                                    | 89.13 (69.49, 114.32)                             |
| Vox       | Cmx (ng/mL)    | 230.8 (84.3)                                                 | 191.6 (85.8)                                     | 119.68 (89.92,159.30)                             |
| Vox       | Cuu (ng/mL)    | 23.7 (71.5)                                                  | 46.7 (82.0)                                      | 51.89 (41.05, 65.59)                              |

CI=confidence interval; %CV=percentage coefficient of variation:FDC=fixed-dose combination; GMR=geometric mean

ratio;PK=pharmacokinetic;SOF=sofosbuvir,VEL=velpatasvir;VOX=voxilaprevir SOF/VEL/VOXadultpopulation includedHCV-infectedadult subjects administeredSOF400mg,VEL100mg,and VOX 100 mg as either single agents or FDC in Phase 2 and 3 Studies GS-US-337-1468, GS-US-367-1168,GS-US-367-1169, GS-US-367-1170,GS-US-367-1171, GS-US-367-1172, GS-US-367-1173,or GS-US-367-1871. Cmin derived from populationPK model is equivalent to Cau.

<div style=\"page-break-after: always\"></div>

A qualitative comparison of observed VOX concentration against time after last dose (TALD) in noncirrhotic adults with adolescents y is shown in Figure 4 below. The observed concentrations of the adolescents are fully contained within the adult range and display a similar trend. This is further corroborated by the corresponding descriptive statistics summarized by TALD windows in Table  below, indicating similar distribution of concentrations between the 2 populations within each TALD window.

<!-- image -->

SOF/VEL/VOX Adult Population = HCV-infected adult subjects administered SOF 400mg, VEL 100mg. VOX 100mg as either single agents or FDC in Phase 2/3

Study GS-US-337-1468, GS-US-367-116S, GS-US-367-1169, GS-US-367-1170, GS-US-367-1171, GS-US-367-1172, GS-US367-1173, or GS-US-367-1871.

Figure 4: Scatter plot between VOX concentration (ng/mL) and time after last Vosevi dose (hours) Adolescent Population vs SOF/VEL/VOX non-cirrhotic adult population (PK analysis set)

Table 5: Summary Statistics of VOX concentration (ng/mL) and time after last Vosevi Dose (hours) Adolescent subjects vs Noncirrhotic Adult Phase 2/3 SOF/VEL/VOX subjects (Population PK Analysis Set)

|          | VOX   | VOX    | VOX    | VOX    | VOX   | VOX    | VOX    | VOX    | VOX     | VOX     | VOX     | VOX     | VOX     | VOX     |
|----------|-------|--------|--------|--------|-------|--------|--------|--------|---------|---------|---------|---------|---------|---------|
| TALD (h) | [0,1] | [0,1]  | [1,2)  | [1,2)  | [2,8) | [2,8)  | [8,16) | [8,16) | [16,24) | [16,24) | [24,32) | [24,32) | [32,51] | [32,51] |
|          | Adol  | Adult  | Adol   | Adult  | Adol  | Adult  | Adol   | Adult  | Adol    | Adult   | Adol    |         | Adol    |         |
| N        | 39    | 685    | 20     | 857    | 63    | 1850   | 25     | 590    | 26      | 1270    | 39      | 368     | 6       | 51      |
| Min      | 6.7   | 1.0    | 13.0   | 0.8    | 15.0  |        | 15.6   | 4.2    | 6.0     | 2.2     | 5.9     | 2.4     | 3.0     | 1.7     |
| Median   | 21.8  | 30.0   | 41.5   | 69     | 95.3  | 117.0  | 77.8   | 68.3   | 28.9    | 31.8    | 17.9    | 22.8    | 8.7     | 10.5    |
| Max      | 271.0 | 1130.0 | 1000.0 | 1800.0 | 869.0 | 2990.0 | 292.0  | 1080.0 | 126.0   | 1510.0  | 95.5    | 3440.0  | 30.8    | 68.5    |

Adol = adolescent; N = number of observations; SOF = sofosbuvir; TALD = time after last dose; VEL = velpatasvir; VOX = Voxilaprevir

SOF/VEL/VOX adult population included HCV-infected adult subjects administered SOF 400 mg, VEL 100 mg, and VOX 100 mg as either single agents or FDC in Phase 2 and 3 Studies GS-US-337-1468, GS-US-367-1168, GS-US-367-1169, GS-US-367-1170,GS-US-367-1171,GS-US-367-1172,GS-US-367-1173,or GS-US-367-1871.

<div style=\"page-break-after: always\"></div>

## 2.4.3. Discussion on clinical pharmacology

Since there is not enough efficacy and safety data in adolescent, the CHMP agreed that efficacy and safety will be extrapolated from adults to adolescents based on the principle of comparable systemic exposure (PK bridge).

The simulated exposure for SOF, the main metabolite of SOF (GS-331007) and VEL show higher exposure in adolescents compared to adults. The proposed posology is the same as what has previously been deemed adequate in paediatric patients for combination including SOF and VEL (Epclusa). The higher exposure in adolescents compared to adults is not considered a concern with regards to safety. Thus, the proposed posology in adolescents regarding SOF and VEL is accepted.

For VOX popPK model, the stratified VPCs show that Cmax is not well captured, underpredicting Cmax for lower body weight patients and overpredicting Cmax for higher body weight patients. Cmin median appears to be fairly well described however the variability is overpredicted, this may be the reason for the 33% lower Cmin in adolescents based on the popPk analysis.

Overall, the VOX popPK model is not optimal and could be further developed/improved. No conclusions here are based on the popPk analysis for VOX. If the VOX model is to be used in the future, improvement of the model is warranted. The CHMP was of the view that this issue does not need to be pursued further in the context of this procedure.

The observed PK data for VOX is deemed rich enough to draw conclusions in adolescents and the exposure is overlapping with adult exposure. The MAH´s conclusion that the VOX exposures in adolescents are similar to those in non-cirrhotic adults for which safety and efficacy have been established was endorsed by the CHMP.

No relative bioavailability study was performed in order to investigate interchangeability of two tablets of the 200/50/50 mg strength and one tablet of the 400/100/100-mg strength. Based on the available data and the input from the QWP and PKWP, the CHMP concluded that a biowaiver for the lowerstrength was justified, as detailed in section 2.2.3 of the CHMP AR.

## 2.4.4. Conclusions on clinical pharmacology

Overall, the PK analyses were considered supportive of the dosing recommendations in the target patient population.

## 2.5. Clinical efficacy

## 2.5.1. Dose response studies and main clinical studies

The current application is based on data from the Phase 2, Open-Label, Multicentre, Multi-cohort Study GS-US-367-1175 (the study was conducted in compliance with GCP);

- to support the extension of the indication to paediatric patients 12 to &lt; 18 years old and weighing at least 30 kg by adding clinical data to the existing marketing authorisation (Vosevi 400 mg/ 100 mg/ 100 mg)
- to introduce a new low dose tablet (Vosevi 200 mg/ 50 mg/ 50 mg)

In the current application, the Applicant included data on PK, safety and efficacy of Vosevi in patients 12 years old to &lt;18 years from the GS-US-367-1175 study.

<div style=\"page-break-after: always\"></div>

Efficacy and safety is being extrapolated from adults to adolescents based on the principle of comparable systemic exposure (PK bridge) in line with the EMA HCV guidelines.

## Main study

Study GS-US-367-1175 : A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination in Adolescents and Children with Chronic HCV Infection

This was an open-label, multi-cohort study evaluating the PK, safety, and antiviral activity of SOF/VEL/VOX for 8 weeks (DAA-naive without compensated cirrhosis) or 12 weeks (DAA-experienced with or without compensated cirrhosis or treatment-naive with compensated cirrhosis) in paediatric subjects with chronic HCV infection. A total of 21 adolescent subjects 12 to &lt; 18 years old were enrolled in the study and received SOF/VEL/VOX for 8 weeks. All 21 subjects completed study drug and were included in both the FAS and the Safety Analysis Set.

## Methods

## Study Participants

## Main Inclusion Criteria

Eligible subjects were males or nonpregnant females 12 to &lt; 18 years old with chronic HCV infection (HCV RNA ≥ 1000 IU/mL) of any HCV genotype, including indeterminate or mixed genotypes, with or without direct-acting antiviral (DAA) experience.

## Main Exclusion Criteria

- Current or prior history of clinical hepatic decompensation
- Any of the following laboratory parameters at screening:
- a) International normalized ratio (INR) &gt; 1.2 x upper limit of normal (ULN)
- b) Platelets &lt; 50,000/mm3
- c) Albumin &lt; 3.5 g/dL
- d) ALT &gt; 10 x ULN
- e) AST &gt; 10 x ULN
- f) Direct bilirubin &gt; 1.5 x ULN

g) Estimated glomerular filtration rate (eGFR) &lt; 90 mL/min/1.73m 2 , as calculated by the Schwartz formula

- Chronic liver disease of a non-HCV aetiology
- Evidence of hepatocellular carcinoma or other malignancy
- Coinfection with HIV, acute hepatitis A virus, or hepatitis B virus (HBV) (hepatitis B surface antigen [HBsAg]-positive at screening)
- Current or prior history of clinically significant illness or major medical disorder
- Clinically relevant alcohol or drug abuse within 12 months of screening.

<div style=\"page-break-after: always\"></div>

Approximately 60 subjects were planned to be enrolled into 3 sequential age-based cohorts as follows:

- Cohort 1: at least 20 subjects 12 to &lt; 18 years old
- Cohort 2: at least 20 subjects 6 to &lt; 12 years old
- Cohort 3: at least 20 subjects 3 to &lt; 6 years old

A modification to the original PIP has been agreed with the European Medicines Agency (EMA) Paediatric Committee (PDCO) decision received on 06 January 2020 (EMEA-001822-PIP01-15-M01), waiving the inclusion of subjects 3 to &lt; 12 years old. Thus, there will be no enrolment into Cohort 2 and Cohort 3.

## Description of Study Procedures

All subjects were to complete the following visits: screening, Day 1, Weeks 1, 2, 4, and 8 or 12 (depending on treatment assignment) during the treatment phase, followed by posttreatment visits at 4, 12, and 24 weeks after discontinuation of study drug.

At least 10 subjects in each age cohort were to be enrolled in an intensive PK substudy conducted at Week 2 or Week 4 after providing separate consent. Sparse PK samples were also collected at Weeks 1, 2, 4, 8, and 12 depending on treatment duration and intensive PK substudy participation.

Pharmacokinetic and safety data from at least 20 evaluable subjects in each cohort were to be reviewed to confirm the appropriateness of the SOF/VEL/VOX dose used.

Subjects who provided separate and specific consent were eligible for participation in the pharmacogenomics substudy. A blood sample was drawn for this substudy at the Day 1 visit or at any time during the study.

After completing all required study visits, all subjects (those who attained SVR24 and those who did not attain SVR24 and did not initiate other experimental or approved anti-HCV therapy) were eligible to enrol into a registry study (GS-US-334-1113) to be followed every 6 months for the first 2 years, then every 12 months for a total of up to 5 years, for assessments of growth, quality of life, and longterm viral suppression (if applicable).

This study was conducted at a total of 10 study centres in Italy, Poland, and United Kingdom.

## Treatments

The marketed dose of SOF/VEL/VOX for the treatment of HCV infection in adults is 400/100/100 mg. The adult clinical dose was evaluated in adolescent subjects (12 to &lt;18 years old) in this study.

Subjects completed a swallowability assessment at screening up to Day 1 using a placebo-to-match (PTM) SOF/VEL/VOX FDC (400/100/100 mg) tablet to determine which formulation each subject could take. Subjects unable to swallow the PTM were to be assigned to wait until a smaller, lower-dose tablet or non-tablet formulation was available.

Following screening and confirmation of eligibility by the investigator, all subjects received the SOF/VEL/VOX FDC (400/100/100 mg) tablet orally once daily with food. Subjects without cirrhosis who were DAA-naive were to receive SOF/VEL/VOX for 8 weeks. Subjects with cirrhosis who were DAAnaive and all DAA-experienced subjects (with or without cirrhosis) were to receive SOF/VEL/VOX for 12 weeks.

All patients were DAA-naïve and without cirrhosis and thus received 8 weeks of treatment.

<div style=\"page-break-after: always\"></div>

All subjects were able to swallow the SOF/VEL/VOX FDC (400/100/100 mg) tablet; therefore, information regarding the low-dose tablet is not presented by the Applicant.

## Objectives

According to the 2016 EMA draft 'Guidelines on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis', similar to the case with HIV, it is considered that efficacy data may be bridged from adults to children, provided that similar drug exposure is reached in plasma at the recommended doses. Paediatric studies could primarily focus on the determination of PK, but would also collect, albeit in a rather limited fashion, data on safety and efficacy.

The recommended primary efficacy endpoint for studies aiming at defining cure rate is SVR, defined as HCV-RNA &lt; LLOQ 12 weeks after the planned completion of therapy (SVR12). Both efficacy and safety endpoints are well-established in the field of hepatitis C clinical trials and the objectives are in line with the overall approach to bridge both efficacy and safety from the adult to the paediatric population.

The primary objective of this study was as follows:

- To evaluate the steady-state pharmacokinetics (PK) and confirm the age-appropriate dose of sofosbuvir (SOF)/velpatasvir (VEL)/voxilaprevir (VOX) fixed-dose combination (FDC) in paediatric subjects with chronic hepatitis C virus (HCV) infection

The secondary objectives of this study were as follows:

- To evaluate the safety and tolerability of SOF/VEL/VOX FDC in paediatric subjects with chronic HCV infection
- To evaluate the antiviral efficacy of SOF/VEL/VOX FDC treatment in paediatric subjects with chronic HCV infection, as assessed by the proportion of paediatric subjects with sustained virologic response (SVR) 12 weeks after cessation of treatment (SVR12)
- To evaluate the antiviral efficacy of SOF/VEL/VOX FDC treatment in paediatric subjects with chronic HCV infection, as assessed by the proportion of paediatric subjects with SVR 4 and 24 weeks after cessation of treatment (SVR4 and SVR24)
- To evaluate the proportion of paediatric subjects with virologic failure, including on-treatment virologic failure and relapse
- To evaluate the kinetics of circulating HCV RNA during treatment and after cessation of treatment
- To evaluate the emergence of viral resistance to SOF, VEL, and VOX during treatment and after cessation of treatment
- To evaluate the effect of SOF/VEL/VOX FDC on growth and development of paediatric subjects during and after treatment
- To evaluate acceptability, including palatability, and swallowability of formulations (as applicable) used in the study
- To assess the effect of treatment with SOF/VEL/VOX FDC on quality of life as measured by the Pediatric Quality of Life Inventory™ v4.0 Short Form 15 (PedsQL™ 4.0 SF15)

<div style=\"page-break-after: always\"></div>

The exploratory objective of this study was as follows:

- To identify or validate genetic markers that may be predictive of the natural history of disease, response to therapy, and/or tolerability of medical therapies through genetic discovery research (eg, pharmacogenomics) in subjects who provided their separate and specific consent

## Outcomes/endpoints

## Safety Assessment

Safety assessments included monitoring of adverse events (AEs) and concomitant medications, clinical laboratory analyses, Tanner pubertal stage assessments, height and weight measurements, vital signs measurements, and physical examinations. Additional safety data related to growth were assessed based on radiographic bone age (end of treatment) and bone age biomarkers (posttreatment Week 24). Neuropsychiatric assessment was done using the PedsQL 4.0 SF15.

All enrolled subjects who received at least 1 dose of study drug were included in the Safety Analysis Set. Safety data included all data collected on or after the first dose of any study drug up to the date of the last dose of study drug plus 30 days. Adverse events were coded using the Medical Dictionary for Regulatory Activities (MedDRA), Version 22.1.

## Efficacy Assessment

The key efficacy endpoint was SVR12, defined as HCV RNA &lt; LLOQ (ie, &lt; 15 IU/mL) 12 weeks after discontinuation of the study drug, in the Full Analysis Set. The point estimates of the SVR12 rate and 2-sided 95% exact CIs based on the Clopper-Pearson method were provided by HCV genotype 1 (further broken down to 1a and 1b), 2, 3, 4, 5, 6, or other, as appropriate, and total.

Secondary efficacy endpoints included the proportion of subjects with SVR4 and SVR24, proportion of subjects with HCV RNA &lt; LLOQ by study visit, HCV RNA absolute values and changes from baseline through end of treatment, proportion of subjects with virologic failure, proportion of subjects with alanine aminotransferase (ALT) normalization, and characterization of baseline, on-treatment, and posttreatment HCV drug resistance substitutions.

All continuous endpoints were summarized using descriptive statistics (sample size, mean, SD, median, first quartile [Q1], third quartile [Q3], minimum, and maximum). All categorical endpoints were summarized by the number and percentage of subjects who met the endpoint definition.

## Sample size

As the efficacy will be bridged through PK, the studies are not powered to allow a precise estimation of neither efficacy nor safety. According to the 2016 EMA draft 'Guidelines on the clinical evaluation of direct acting antivirals for the treatment of chronic hepatitis' it is recognised that the number of children and adolescents with chronic hepatitis C eligible for clinical trials is limited. If there are no specific safety concerns relevant to the paediatric population, pre-authorisation studies could be limited in size.

Number of Subjects (Planned and Analysed):

Planned: Approximately 20 subjects 12 to &lt; 18 years old

<div style=\"page-break-after: always\"></div>

## Analysed:

- Full Analysis Set: 21 subjects
- Safety Analysis Set: 21 subjects
- PK Analysis Set: 21 subjects
- Intensive PK Analysis Set: 14 subjects

At least 10 subjects in each age cohort were to be enrolled in an intensive PK substudy conducted at Week 2 or Week 4 after providing separate consent. Sparse PK samples were also collected from all subjects at Weeks 1, 2, 4, 8, and at end of treatment or early termination, depending on treatment duration and intensive PK substudy participation.

## Randomisation and blinding (masking)

Study GS-US-367-1175 was an open-label, single-arm study, hence no randomisation.

## Statistical methods

The statistical methods applied are standard for this type of study and they are considered acceptable. The statistical methods were detailed in the SAP, the SAP was however finalised close to the database lock date. Given the open label nature of the study an earlier finalization of the SAP would have been preferred but since the efficacy endpoints are objective in nature this is of less concern.

## Sample Size and Power

Assuming similar variability for SOF, GS-331007, VEL, and VOX AUCtau in the paediatric population compared with adults, a sample size of 20 paediatric subjects per cohort provided at least 80% power to target a 90% CI of the geometric mean ratio (GMR) within the bounds of 50% to 200%.

## Analysis Sets

The Full Analysis Set (FAS) included all enrolled subjects who took at least 1 dose of study drug (SOF/VEL/VOX FDC). This was the primary analysis set for efficacy analyses.

The Safety Analysis Set included all subjects who were enrolled into the study and took at least 1 dose of study drug (SOF/VEL/VOX FDC). This was the primary analysis set for safety analyses.

## Missing data handling

For the analyses of categorical HCV RNA data, missing posttreatment HCV RNA data will have the missing data imputed. Missing on-treatment HCV RNA will have the missing data imputed up to the time of the last dose. If a data point is missing and is preceded and followed in time by values that are '&lt; LLOQ target not detected (TND),' then the missing data point will be set to '&lt; LLOQ TND.' If a data point is missing and preceded and followed by values that are '&lt; LLOQ detected,' or preceded by '&lt; LLOQ detected' and followed by '&lt; LLOQ TND,' or preceded by '&lt; LLOQ TND' and followed by '&lt; LLOQ detected,' then the missing value will be set to '&lt; LLOQ detected.' In these situations, the data point will be termed a bracketed success; otherwise, the data point will be termed a bracketed failure (i.e., ≥ LLOQ detected). If a data point is missing and is not bracketed, the missing data point will also be termed a failure (i.e., ≥ LLOQ detected) except for SVR24, which will be imputed according to the SVR12 status. Success for SVR12 who have no further HCV RNA measurements collected will be counted as a success for SVR24 due to the high correlation between these 2 endpoints.

## Statistical analysis of efficacy endpoint

<div style=\"page-break-after: always\"></div>

The proportion of subjects with sustained virological response (SVR) 12 weeks after cessation of treatment (SVR12) was summarized. The point estimates of SVR12 rate and 2- sided 95% exact CI based on Clopper-Pearson method was provided by HCV genotype (1 [further broken down to 1a and 1b], 2, 3, 4, 5, 6, or other, as appropriate, and total).

No adjustments for multiple comparisons were performed.

## Results

## Participant flow

Table 6: Disposition of Subjects (Screened Subjects)

|                                           | 12 to<18YearsOld SOF/VEL/VOXFDC (400/100/100 mg) 8 Weeks   |
|-------------------------------------------|------------------------------------------------------------|
| Subjects Screened                         | 21                                                         |
| Subjects Enrolled                         | 21                                                         |
| Subjects Enrolled but Never Treated       | 0                                                          |
| Subjects in Safety Analysis Set           | 21                                                         |
| Subjects in Full Analysis Set             | 21                                                         |
| Subjects in PK Analysis Set               | 21                                                         |
| Subjects in Intensive PK Analysis Set     | 14                                                         |
| Study Treatment Status                    |                                                            |
| Completed Study Treatment                 | 21 (100.0%)                                                |
| NoFU-4HCV RNAAssessment                   | 0                                                          |
| WithFU-4 but noFU-12 HCV RNAAssessment    | 0                                                          |
| Discontinued Study Treatment              | 0                                                          |
| No FU-4 HCV RNA Assessment                | 0                                                          |
| With FU-4 but no FU-12 HCV RNA Assessment | 0                                                          |
| Study Status                              |                                                            |
| Completed Study                           | 21 (100.0%)                                                |
| Discontinued Study                        | 0                                                          |

FDC = fixed-dose combination; FU-x = follow-up visit at x weeks after discontinuing treatment; HCV = hepatitis C virus; PK = pharmacokinetic; SOF = sofosbuvir; VEL = velpatasvir; VOX = voxilaprevir Thedenominatorforpercentagesisbased onthenumber ofsubjectsintheSafetyAnalysisSet. SafetyAnalysis Set includes subjects who took at least 1 dose of study drug (ie, SOF/VEL/VOX FDC). Full Analysis Set includes subjects who were enrolled into the study and received at least one dose of study drug. PK Analysis Set includes all enrolled subjects who received at least one dose of study drug and for whom at least one nonmissing PK concentration data value is available from all types of PK sampling. Source:Table 15.8.1

## Protocol Deviation

A total of 2 important protocol deviations occurred in 2 subjects during the study. One subject was enrolled without completing alcohol or drug abuse screening during the screening visit, so confirmation of this exclusion criterion was not performed prior to enrolment. The other deviation was due to a site failing to electronically transmit an SAE eCRF to the relevant safety group within 24 hours of being informed of the event, as required. Neither of these important protocol deviations affected the overall quality or interpretation of the study data.

<div style=\"page-break-after: always\"></div>

## Recruitment

Table 7: Key Dates Relevant to the Conduct of Study GS-US-367-1175

| Event                                                | Date             |
|------------------------------------------------------|------------------|
| FirstSubjectScreened                                 | 28January2019    |
| FirstSubjectEnrolled                                 | 12 February 2019 |
| LastSubjectEnrolled                                  | 16 July 2019     |
| Last Subject Last Observation for thePrimaryEndpoint | 04December2019   |
| LastSubjectLastObservationforthisReport              | 19 February 2020 |
| DatabaseFinalization                                 | 29 April 2020    |

## Conduct of the study

The protocol was amended once during the course of Study GS-US-367-1175, as indicated in the Table below.

Table 8: Protocol amendments

| Protocol/Amendment         | Date            |
|----------------------------|-----------------|
| Original                   | 08February 2018 |
| Amendment1SummaryofChanges | 27March 2019    |
| Amendment1                 | 27March 2019    |
| AdministrativeAmendment2   | 11October2019   |

Administrative Amendment 1 (04 March 2019) was incorporated into Amendment 1.

Summary of the major changes made to the Original Protocol dated 08 February 2018 and reflected in Amendment 1.0 dated 27 March 2019 are presented below.:

## New Information

- Approximate amount of blood drawn at each visits, which has been reduced to align with the paediatric EMEA guidance 'Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate' dated 25 June 2009 which recommends that the trial-related blood loss should not exceed 3 % of the total blood volume during a period of four weeks and should not exceed 1 % at any single time.
- Weight related inclusion criteria for subjects participating in the Intensive PK Substudy in each cohort, to align with EMEA guidance 'Guideline on the Investigation of Medicinal Products in the Term and Preterm Neonate' dated 25 June 2009.

## Clarifications

- Clarification on possible impact of the IMP on P-gp, BCRP, OATP1B1, OATP1B3, or OATP2B1 substrates, as described in the Investigator Brochure
- Discontinuation criteria related to Grade 3 and Grade 4 adverse events: reference to Appendix 3 table added
- Further details concerning dose calculation for Cohort 2 and 3

<div style=\"page-break-after: always\"></div>

## Updates

- Change of Gilead Study director and medical Monitor
- Disallowed and Concomitant Medication Table, to align with Vosevi EU SmPC

The statistical analysis plan is dated 10 April 2020 and the study report is dated 24 June 2020.

## Baseline data

Table 9: Demographic and Baseline Characteristics (Safety Analysis Set)

| Characteristic            | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Weeks Total (All Genotypes) (N = 21)   |
|---------------------------|-----------------------------------------------------------------------------------------|
| Age at Baseline (Years)   |                                                                                         |
| N                         | 21                                                                                      |
| Mean (SD)                 | 14 (1.2)                                                                                |
| Median                    | 14                                                                                      |
| Q1, Q3                    | 13, 14                                                                                  |
| Min, Max                  | 12, 16                                                                                  |
| Sex at Birth              |                                                                                         |
| Male                      | 8 (38.1%)                                                                               |
| Female                    | 13 (61.9%)                                                                              |
| Race                      |                                                                                         |
| White                     | 16 (76.2%)                                                                              |
| Black or African American | 1 (4.8%)                                                                                |
| Asian                     | 2 (9.5%)                                                                                |
| Other                     | 2 (9.5%)                                                                                |

| Characteristic                   | 12 to<18Years Old SOF/VEL/VOXFDC (400/100/100mg) 8 Weeks Total (All Genotypes) (N =21)   |
|----------------------------------|------------------------------------------------------------------------------------------|
| American Indian or Alaska Native | 0                                                                                        |
| NativeHawaian orPacificIslander  | 0                                                                                        |
| Ethnicity                        |                                                                                          |
| Hispanic or Latino               | 2 (9.5%)                                                                                 |
| Not Hispanic or Latino           | 19 (90.5%)                                                                               |
| Baseline Weight (kg)             |                                                                                          |
| N                                | 21                                                                                       |
| Mean (SD)                        | 54.0 (11.39)                                                                             |
| Median                           | 54.2                                                                                     |
| Q1, Q3                           | 46.1, 57.8                                                                               |
| Min, Max                         | 38.2, 86.2                                                                               |

FDC = fixed-dose combination; N = number of subjects; Q1 = first quartile; Q3 = third quartile; SOF = sofosbuvir;

Baseline value is the last available value on or prior to first dose date of study drug.

Source:GS-US-367-1175 CSR,Table 15.8.4

VEL = velpatasvir; VOX = voxilaprevir

<div style=\"page-break-after: always\"></div>

Table 1: Baseline Disease Characteristics (Safety Analysis Set)

| Characteristic              | 12 to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Weeks Total (All Genotypes) (N=21)   |
|-----------------------------|----------------------------------------------------------------------------------------|
| Sequence based HCV Genotype |                                                                                        |
| Genotype 1                  | 6 (28.6%)                                                                              |
| Genotype la                 | 2 (33.3%)                                                                              |
| Genotype Ib                 | 4 (66.7%)                                                                              |
| Genotype 2                  | 4 (19.0%)                                                                              |

|                                           | 12 to<18YearsOld SOF/VEL/VOXFDC(400/100/100mg) 8 Weeks   |
|-------------------------------------------|----------------------------------------------------------|
| Characteristic                            | Total (All Genotyp es) (N =21)                           |
| Genotype 3                                | 9 (42.9%)                                                |
| Genotype 4                                | 2 (9.5%)                                                 |
| Cirrhosis                                 |                                                          |
| Yes                                       | 0                                                        |
| No                                        | 21 (100.0%)                                              |
| FibroScan (Transient Elastography) in kPa |                                                          |
| N                                         | 7                                                        |
| Mean (SD)                                 | 5.8 (1.08)                                               |
| Median                                    | 5.6                                                      |
| Q1,Q3                                     | 4.9, 6.1                                                 |
| Min, Max                                  | 4.6, 7.9                                                 |
| Fibrotest Score                           |                                                          |
| N                                         | 21                                                       |
| Mean (SD)                                 | 0.2 (0.10)                                               |
| Median                                    | 0.2                                                      |
| Q1,Q3                                     | 0.1,0.3                                                  |
| Min, Max                                  | 0.1,0.5                                                  |
| Fibrotest Stage                           |                                                          |
| FO, no or minimal fibrosis                | 15 (71.4%)                                               |
| F0-F1, no orminimal fibrosis              | 2 (9.5%)                                                 |
| F1, no orminimal fibrosis                 | 3 (14.3%)                                                |
| F1-F2, moderate fibrosis                  | 1 (4.8%)                                                 |
| APRI                                      |                                                          |
| N                                         | 21                                                       |
| Mean (SD)                                 | 0.3 (0.16)                                               |
| Median                                    | 0.2                                                      |
| Q1,Q3                                     | 0.2,0.3                                                  |
| Min, Max                                  | 0.2,0.8                                                  |
| FIB-4                                     |                                                          |
| N                                         | 21                                                       |
| Mean (SD)                                 | 0.3 (0.10)                                               |
| Median                                    | 0.3                                                      |
| Q1,Q3                                     | 0.2,0.3                                                  |
| Min, Max                                  | 0.2,0.5                                                  |
| Baseline HCV RNA Category                 |                                                          |

<div style=\"page-break-after: always\"></div>

|                                     | 12to<18YearsOld SOF/VEL/V0X FDC (400/100/100mg) 8 Weeks   |
|-------------------------------------|-----------------------------------------------------------|
| Characteristic                      | Total (All Genotypes) (N =21)                             |
| <800,000 IU/mL                      | 10 (47.6%)                                                |
| 2 800,000 IU/mL                     | 11 (52.4%)                                                |
| Bascline HCV RNA (logl0 IU/mL)      |                                                           |
| N                                   | 21                                                        |
| Mean (SD)                           | 5.9 (0.70)                                                |
| Median                              | 6.0                                                       |
| Q1, Q3                              | 5.5,6.4                                                   |
| Min, Max                            | 4.3, 7.1                                                  |
| Bascline ALT (U/L)                  |                                                           |
| N                                   | 21                                                        |
| Mcan (SD)                           | 39 (27.5)                                                 |
| Median                              | 29                                                        |
| Q1, Q3                              | 19, 41                                                    |
| Min, Max                            | 15, 108                                                   |
| Baseline ALT Category               |                                                           |
| ≤ 1.5 x ULN                         | 16 (76.2%)                                                |
| >1.5 x ULN                          | 5 (23.8%)                                                 |
| Prior HCV Treatment Experiencc      |                                                           |
| Treatment-Naive                     | 16/21 (76.2%)                                             |
| Treatment-Experienced               | 5/21 (23.8%)                                              |
| Direct-Acting Antiviral-Naive       | 5/5 (100.0%)                                              |
| Direct-Acting Antiviral-Experienced | 0/5                                                       |
| Mode of HCV Infection               |                                                           |
| Blood Product Transfusion           | 1 (4.8%)                                                  |
| Contact with Infected Individual    | 1 (4.8%)                                                  |
| Unknown                             | 3 (14.3%)                                                 |
| Vertical Transmission               | 16 (76.2%)                                                |

ALT = alanine aminotransferase; APRI = aspartate aminotransferase (AST) to platelet ratio index; FIB-4 =Fibrosis-4; HCV = hepatitis C virus; FDC = fixed-dose combination; N= number of subjects; Q1 = first quartile; Q3 = third quartile; SOF = sofosbuvir; ULN = upper limit of normal; VEL = velpatasvir; VOX = voxilaprevir Baseline value is the last available value on or prior to first dose date of study drug. Source:GS-US-367-1175 CSR, Table 15.8.4

The study population had mild disease, which can be anticipated in the paediatric population.

<div style=\"page-break-after: always\"></div>

Table 2: Adherence to Study Drug (Safety Analysis Set)

|                                         | 12 to < 18 Years Old SOF/VEL/V0X FDC (400/100/100 mg) 8 Weeks (N = 21)   |
|-----------------------------------------|--------------------------------------------------------------------------|
| Study Drug Adherence Rate (%)           |                                                                          |
| N                                       | 21                                                                       |
| Mean (SD)                               | 95.2 (14.48)                                                             |
| Median                                  | 100.0                                                                    |
| Q1, Q3                                  | 100.0, 100.0                                                             |
| Min, Max                                | 50.0, 100.0                                                              |
| Study DrugAdherence Rate                |                                                                          |
| < 80%                                   | 2 (9.5%)                                                                 |
| ≥ 80 to < 90%                           | 0                                                                        |
| ≥ 90%                                   | 19 (90.5%)                                                               |
| At Least 80% Adherence to Study Regimen | 19 (90.5%)                                                               |

FDC = fixed-dose combination; N = number of subjects; Q1 = first quartile; Q3 = third quartile; SOF = sofosbuvir;

VEL = velpatasvir; VOX =voxilaprevir

Adherence to study drug calculated to Day 56.

If a bottle was dispensed but not returned (missing), then it was assumed that no study drug was taken from that bottle.

Source: Table 15.8.5

## Numbers analysed

- Full Analysis Set: 21 subjects

- Safety Analysis Set: 21 subjects

- •

- PK Analysis Set: 21 subjects

- •

- Intensive PK Analysis Set: 14 subjects

## Outcomes and estimation

Different genotypes were represented in the study population, as shown in Table  below.

<div style=\"page-break-after: always\"></div>

Table 3: Virologic Outcomes by Genotype (Full Analysis Set)

|                           | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100mg) 8 Wecks   |
|---------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
|                           | Total (All Genotypes) (N = 21)                           | GT-1a (N=2)                                              | GT-1b (N=4)                                              | GT-1 Total (N=6)                                         | GT-2 (N =4)                                              | GT-3 (N =9)                                              | GT-4 (N= 2)                                              |
| SVR12                     | 21/21 (100.0%)                                           | 2/2 (100.0%)                                             | 4/4 (100.0%)                                             | 6/6 (100.0%)                                             | 4/4 (100.0%)                                             | 9/9 (100.0%)                                             | 2/2 (100.0%)                                             |
| Overall Virologic Failure | 0/21                                                     | 0/2                                                      | 0/4                                                      | 0/6                                                      | 0/4                                                      | 0/9                                                      | 0/2                                                      |
| Other                     | 0/21                                                     | 0/2                                                      | 0/4                                                      | 0/6                                                      | 0/4                                                      | 0/9                                                      | 0/2                                                      |

FDC = fixed-dose combination; GT = genotype; HCV = hepatitis C virus; LLOQ = lower limit of quantitation; N = number of subjects; SOF = sofosbuvir; SVR12 = sustained virologic response at 12 weeks following discontinuation of study drug;

VEL = velpatasvir; VOX = voxilaprevir

HCV RNA was analyzed using COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.0 with limit of quantitation 15 IU/mL.

Source:GS-US-367-1175 CSR,Table 15.9.2

Table 4: SVR by Visit During Post-treatment Follow-Up (Full Analysis Set)

|        | 12 to<18YearsOld SOF/VEL/VOX FDC (400/100/100 mg) 8 Weeks (N =21)   |
|--------|---------------------------------------------------------------------|
| SVR4   | 21/21 (100.0%)                                                      |
| 95% CI | 83.9% to 100.0%                                                     |
| SVR12  | 21/21 (100.0%)                                                      |
| 95% CI | 83.9% to 100.0%                                                     |
| SVR24  | 21/21 (100.0%)                                                      |
| 95% CI | 83.9% to 100.0%                                                     |

FDC = fixed-dose combination; HCV = hepatitis C virus; LLOQ = lower limit of quantitation; N = number of subjects;

SOF = sofosbuvir; SVRxx = sustained virologic response at xx weeks following discontinuation of study drug; TND = target not detected; VEL = velpatasvir; VOX = voxilaprevir

HCV RNA was analyzed using COBAS?AmpliPrep?/COBAS? TaqMan? HCV Quantitative Test, v2.0 with limit of quantitation 15 IU/mL.

SVRxx was sustained virologic response (HCV RNA &lt; LLOQ) xx weeks after stopping study treatment.

The exact 95% CI for the proportion within treatment group was based on the Clopper-Peaison method.

A missing SVR value was imputed as a success if it was bracketed by values that were termed successes (ie, \"&lt;LLOQ TND\" or \"&lt;LLOQ detected\"); otherwise, the missing SVR value was imputed as a failure.

Source:Table15.9.3

Proportion of Subjects with HCV RNA &lt; LLOQ While on Treatment by Visit

The table below presents the proportion of subjects with HCV RNA &lt; LLOQ while on treatment by analysis visit. The total number of subjects with HCV &lt; LLOQ was the sum of the number of subjects with HCV RNA '&lt; LLOQ detected' plus the number of subjects with HCV RNA '&lt; LLOQ target not detected (TND).' Potent and rapid suppression of HCV RNA while on treatment was observed. At Week 4, 90.5% of subjects (19 of 21) had HCV RNA &lt; LLOQ, and 100.0% of subjects (21 of 21) had HCV RNA &lt; LLOQ at Week 8.

<div style=\"page-break-after: always\"></div>

Table 5: Proportion of Subjects with HCV RNA &lt; LLOQ (15 IU/mL) While on Treatment by Visit (Full Analysis Set)

| Characteristic   | 12to<18YearsOld SOF/VEL/VOX FDC (400/100/100 mg) 8 Weeks (N = 21)   |
|------------------|---------------------------------------------------------------------|
| Baseline         |                                                                     |
| <LLOQ            | 0/21                                                                |
| Week 1           |                                                                     |
| < LLOQ           | 11/21 (52.4%)                                                       |
| 95% CI           | 29.8% to 74.3%                                                      |
| < LLOQ detected  | 8/21 (38.1%)                                                        |
| < LLOQ TND       | 3/21 (14.3%)                                                        |
| Week 2           |                                                                     |
| < LLOQ           | 17/21 (81.0%)                                                       |
| 95% CI           | 58.1% to 94.6%                                                      |
| < LLOQ detected  | 5/21 (23.8%)                                                        |
| < LLOQ TND       | 12/21 (57.1%)                                                       |
| Week 4           |                                                                     |
| <LLOQ            | 19/21 (90.5%)                                                       |
| 95% CI           | 69.6% to 98.8%                                                      |
| < LLOQdetected   | 3/21 (14.3%)                                                        |
| < LLOQ TND       | 16/21 (76.2%)                                                       |
| Week 8           |                                                                     |
| <LLOQ            | 21/21 (100.0%)                                                      |
| 95% CI           | 83.9% to 100.0%                                                     |
| < LLOQdetected   | 1/21 (4.8%)                                                         |
| < LLOQ TND       | 20/21 (95.2%)                                                       |

FDC = fixed-dose combination; HCV = hepatitis C virus; LLOQ = lower limit of quantitation; N = number of subjects;

HCV RNA was analyzed using COBAS AmpliPrep/COBAS TaqMan HCV Quantitative Test v2.O with limit of quantitation 15 IU/mL.

SOF = sofosbuvir; TND = target not detected; VEL = velpatasvir; VOX = voxilaprevir

Missing values for on-treatment visits were imputed up to the time of last dose (if the study day associated with the last dose date is greater than or equal to the lower bound of a visit window, the missing value at the visit was imputed, otherwise, the value was excluded).

Missing values bracketed by values of\"&lt; LLOQ TND\" were set to \"&lt; LLOQ TND\"; bracketed by \"&lt; LLOQ detected\", or \"&lt;LLOQ TND\" and \"&lt;LLOQ detected\" were set to \"&lt;LLOQ detected\"; otherwise, the missing values were set as \"≥ LLOQ.\" The exact 95% CI for the proportion within treatment group was based on the Clopper-Pearson method. Source: Table 15.9.6

## ALT Normalization

At baseline, 23.8% of subjects (5 of 21) had ALT &gt; ULN. Normalization of ALT was observed in all of these subjects at Week 4 and in 4 of 4 subjects (1 missing value) through the - Week 4 visit, coincident with suppression of viral replication.

<div style=\"page-break-after: always\"></div>

## Prevalence of Pre-treatment NS3 and NS5A RAVs and Impact on Treatment Outcome

Pre-treatment full-length NS3 and NS5A deep sequencing data were obtained for all 21 subjects and NS3 and NS5A resistance-associated variants (RAVs) were reported at a 15% assay cut-off. Overall, 1 of 21 subjects (4.8%) had pre-treatment NS3 RAVs without NS5A RAVs. A total of 10 of 21 subjects (47.6%) had pre-treatment NS5A RAVs alone. None of the subjects had both NS3 and NS5A RAVs at baseline. All 11 subjects (52.4%) with baseline NS3 or NS5A RAVs achieved SVR12 and SVR24. Overall, 21 of 21 subjects (100%) achieved SVR12 and SVR24.

## Prevalence of Pre-treatment NS5B NI RAVs and Impact on Treatment Outcome

For the purposes of this report, NS5B NI RAVs were defined as follows: S96T, N142T, L159F, E237G, S282ANY, C289I/L, L320F/I/V, and V321A/I, and were reported at a 15% assay cut off. Pre-treatment full-length NS5B sequencing data were obtained for 21 of 21 subjects. Three of 21 subjects (14.3%) had pre-treatment NS5B NI RAVs detected at baseline at a 15% assay cut off. All 3 subjects with baseline NS5B NI RAVs achieved SVR12 and SVR24.

Overall, fourteen of 21 patients had baseline RAVs which did not impact treatment outcome and all the 21 patients reached SVR12 and SVR24.

## Acceptability

A total of 21 subjects completed the acceptability questionnaire at Day 1, and 20 subjects and 21 parents or guardians completed the questionnaire at end of treatment (Week 8). Overall, the majority of responses were favourable or neutral with respect to acceptability of the SOF/VEL/VOX FDC (400/100/100 mg) tablet.

## Quality of Life Survey

Based on subject and parent/guardian responses to the PedsQL 4.0 SF15 quality of life survey at baseline, end of treatment (Week 8), and posttreatment Weeks 12 and 24, there were no notable changes in overall quality of life or neuropsychiatric status during the study. Based on the subject reports, there was a statistically significant (p = 0.032) increase (improvement) at end of treatment compared with baseline in the psychosocial health summary score, followed by non-statistically significant decreases (worsening) during the posttreatment period. The mean psychosocial health summary scores per the subject reports at posttreatment Weeks 12 and 24 were slightly higher than baseline. No other statistically significant changes were observed.

## Ancillary analyses

With the 100.0% SVR12 rate observed and no cases of virologic failure, no meaningful interpretation of subgroup analyses can be made.

## Analysis performed across trials (pooled analyses and meta-analysis)

Not applicable.

## Clinical studies in special populations

Not applicable.

<div style=\"page-break-after: always\"></div>

## Supportive studies

Not applicable.

## 2.5.2. Discussion on clinical efficacy

## Design and conduct of clinical studies

The GS-US-367-1175 study was not powered for a precise estimate of efficacy and no control arm is available for comparison which is fully acceptable since the main objective of the study is to provide PK data. Furthermore, it was conducted in a population where the contribution of voxilaprevir to the favourable outcomes cannot be ascertained. However, in line with EMA guidance, efficacy can be extrapolated through a PK-bridge as exposure is similar in adolescents and adults.

## Efficacy data and additional analyses

The key efficacy endpoint was SVR12 (HCV RNA &lt; LLOQ 12 weeks after discontinuation of study drug). Overall, 21 of 21 patients 12 &lt;18 years of age achieved SVR12. No subject had virologic failure, there was no on-treatment breakthrough or relapse observed in subjects through posttreatment Week 12 or posttreatment Week 24.

At Week 4, 90.5% of subjects (19 of 21) had HCV RNA &lt; LLOQ, and 100.0% of subjects (21 of 21) had HCV RNA &lt; LLOQ at Week 8.

Normalization of ALT was observed in all subjects at Week 4 through the posttreatment Week 4 visit (final observation), coincident with suppression of viral replication.

Pre-treatment NS3 and NS5A RAVs were observed in 4.8% and 47.6% of subjects with a virologic outcome that were included in the Resistance Analysis Population, respectively. Pre-treatment NS5B NI RAVs were observed in 14.3% of the subjects. The presence of pre-treatment NS3, NS5A, and/or NS5B RAVs did not impact treatment outcome as all subjects with pre-treatment RAVs achieved SVR12 and SVR24.

## 2.5.3. Conclusions on the clinical efficacy

The CHMP concluded that Vosevi is effective in the treatment of chronic HCV in adolescent patients 12 &lt; 18 years of age and weighing at least 30 kg.

## 2.6. Clinical safety

## Patient exposure

The mean (SD) duration of exposure was 8.0 (0.08) weeks. All subjects completed their assigned 8week treatment duration. No subjects were assigned to the 12-week treatment duration.

<div style=\"page-break-after: always\"></div>

Table 6: Duration of Exposure to Study Regimen (Safety Analysis Set)

|                                                               | 12to<18YearsOld SOF/VEL/VOX FDC (400/100/100 mg) 8 Weeks (N = 21)   |
|---------------------------------------------------------------|---------------------------------------------------------------------|
| Duration of Exposure to Study Regimen (Weeks)                 |                                                                     |
| N                                                             | 21                                                                  |
| Mean (SD)                                                     | 8.0 (0.08)                                                          |
| Median                                                        | 8.0                                                                 |
| Q1, Q3                                                        | 8.0, 8.0                                                            |
| Min, Max                                                      | 8.0, 8.3                                                            |
| Cumulative N (%) of Subjects Exposed to Study Regimen Through |                                                                     |
| Baseline                                                      | 21 (100.0%)                                                         |
| Week 1                                                        | 21 (100.0%)                                                         |
| Week 2                                                        | 21 (100.0%)                                                         |
| Week 4                                                        | 21 (100.0%)                                                         |
| Week 8                                                        | 21 (100.0%)                                                         |

FDC = fixed-dose combination; N = number of subjects; Q1 = first quartile; Q3 = third quartile; SOF = sofosbuvir; VEL =velpatasvir; VOX =voxilaprevir

Weeks on study drug = (last dose date of individual study drug - first dose date of individual study drug + 1) divided by 7. A 3-day window is applied to the last planned on-treatment visit to match with the protocol-specified visit window Source: Table 15.10.1

## Adverse events

The majority of subjects (71.4%, 15 of 21) experienced at least 1 AE, and 42.9% of subjects (9 of 21) had a treatment-related AE, as presented in Table  below. All AEs were Grade 1 (mild) or Grade 2 (moderate) in severity. One of 21 subjects (4.8%) experienced an SAE, which was assessed as related to study drug. No subject had an AE that led to premature discontinuation or interruption of study drug. No deaths occurred during the study.

<div style=\"page-break-after: always\"></div>

Table 7: Overall Summary of Adverse Events (Safety Analysis Set)

|                                                                  | 12to<18YearsOld SOF/VEL/VOXFDC (400/100/100 mg) 8 Weeks (N =21)   |
|------------------------------------------------------------------|-------------------------------------------------------------------|
| Number (%) of Subjects Experiencing Any                          |                                                                   |
| Adverse Event                                                    | 15 (71.4%)                                                        |
| Grade 3 or Above Adverse Event                                   | 0                                                                 |
| Grade 2 or Above Adverse Event                                   | 7 (33.3%)                                                         |
| Treatment-RelatedAdverseEvent                                    | 9 (42.9%)                                                         |
| Grade 3 or AboveTreatment-RelatedAdverseEvent                    | 0                                                                 |
| Grade 2 or Above Treatment-Related Adverse Event                 | 1 (4.8%)                                                          |
| Serious Adveise Event                                            | 1 (4.8%)                                                          |
| Treatment-RelatedSeriousAdverseEvent                             | 1 (4.8%)                                                          |
| Adverse Event Leading to Premature Discontinuation of Study Drug | 0                                                                 |
| Adverse Event Leading to Interruption of Study Drug              | 0                                                                 |
| All Deaths                                                       | 0                                                                 |

FDC = fixed-dose combination; N = number of subjects; SOF = sofosbuvir; VEL = velpatasvir; VOX = voxilaprevir

The denominator for percentages is based on the number of subjects in the Safety Analysis Set.

Source:Table15.11.1

## Common Adverse Events

The Table  below presents a summary of AEs reported for ≥ 5% of subjects by PT. The 3 most commonly reported AEs were abdominal pain and headache (23.8%, 5 subjects each) and nausea (19.0%, 4 subjects).

Table 8: Adverse Events Reported for at Least 5% of Subjects by Preferred Term (Safety Analysis Set)

|                                                                                                            | 12 to<18YearsOld SOF/VEL/VOXFDC (400/100/100 mg) 8Weeks (N=21)   |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------|
| Number (%) of Subjects Experiencing Any Adverse Event                                                      | 15 (71.4%)                                                       |
| Number (%) ofSubjects Experiencing Any Adverse Event Occurring in At Least 5% of Subjects byPreferred Term |                                                                  |
| Abdominal pain                                                                                             | 5 (23.8%)                                                        |
| Headache                                                                                                   | 5 (23.8%)                                                        |
| Nausea                                                                                                     | 4 (19.0%)                                                        |
| Diarrhea                                                                                                   | 3 (14.3%)                                                        |
| Fatigue                                                                                                    | 3 (14.3%)                                                        |
| Rhinitis                                                                                                   | 3 (14.3%)                                                        |
| Asthenia                                                                                                   | 2 (9.5%)                                                         |
| Cough                                                                                                      | 2 (9.5%)                                                         |
| Dizziness                                                                                                  | 2 (9.5%)                                                         |

FDC = fixed-dose combination; MedDRA = Medical Dictionary for Regulatory Activities; N = number of subjects;

Adverse events are mapped according to MedDRA Version 22.1.

SOF=sofosbuvir;VEL=velpatasvir;VOX=voxilaprevir

Subjects are counted once foreach AE preferred term.

Data included tolast dose date of study drug+ 30 days.

Source:Table 15.11.2.1

<div style=\"page-break-after: always\"></div>

Overall, the frequency of AEs in Study GS-US-367-1175 are in line with observed AEs in the adult Phase 3 clinical trials. Abdominal pain is more frequently reported in the adolescent population (23.8%) compared to the adult population (3.4% abdominal pain in the Phase 3 program). However, all AEs were Grade 1 (mild) or Grade 2 (moderate) in severity.

## Adverse Events by Severity

All AEs reported in this study were Grade 1 (mild) or Grade 2 (moderate) in severity. No Grade 3 (severe) or Grade 4 (life threatening) AEs were reported.

## Adverse Events by Relationship to Study Drug

The Table  below presents a summary of treatment-related AEs reported for ≥ 5% of subjects by PT. The most common treatment-related AEs reported were headache (14.3%, 3 subjects), nausea (14.3%, 3 subjects), and abdominal pain, diarrhoea, and fatigue (9.5%, 2 subjects each).

Table 18: Treatment-Related Adverse Events Reported for at Least 5% of Subjects by Preferred Term (Safety Analysis Set)

|                                                                                                                                | 12 to<18YearsOld SOF/VEL/VOXFDC (400/100/100 mg) 8 Weeks (N = 21)   |
|--------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|
| Number (%) of Subjects Experiencing Any Treatment-Related Adverse Event                                                        | 9 (42.9%)                                                           |
| Number (%) of Subjects Experiencing Any Treatment-Related Adverse Event Occurring in at Least 5% of Subjects by Preferred Term |                                                                     |
| Headache                                                                                                                       | 3 (14.3%)                                                           |
| Nausea                                                                                                                         | 3 (14.3%)                                                           |
| Abdominal pain                                                                                                                 | 2 (9.5%)                                                            |
| Diarrhea                                                                                                                       | 2 (9.5%)                                                            |
| Fatigue                                                                                                                        | 2 (9.5%)                                                            |

AE = adverse event; FDC = fixed-dose combination; MedDRA = Medical Dictionary for Regulatory Activities; N = number of subjects; SOF = sofosbuvir; VEL = velpatasvir; VOX = voxilaprevir

Adverse events are mapped according to MedDRA Version 22.1.

Subjects are counted once for each AE preferred term.

AEs are related to treatment if Related toStudy Treatment='Related'on the AE case report form.

Data included tolast dose date of study drug+ 30 days.

Source:Table 15.11.5.1

## Discontinuations Due to Adverse Events

No subject discontinued study drug due to an AE.

## Adverse Events Leading to Interruption of Study Drug

There were no AEs leading to interruption of study drug during this study.

<div style=\"page-break-after: always\"></div>

## Analysis of Adverse Events by Organ System or Syndrome

Adverse events of interest were defined as treatment-emergent AEs that have historically been associated with administration of some nucleoside/nucleotide inhibitors or other DAAs including cardiac events, dermatologic events, pancytopenia, psychiatric events relevant to suicide ideation or attempt, pancreatitis events, rhabdomyolysis/myopathy events, renal failure events and hepatic events.

## Cardiac Safety

Cardiac safety assessments included analysis of cardiac failure events, cardiac arrhythmia/bradycardia events, events during the first 2 weeks of study treatment in subjects taking or not taking beta blockers and calcium channel blockers, and any safety events in subjects with amiodarone use during treatment.

Cardiac Failure Events : Given historical potential toxicities associated with some antiviral nucleoside/nucleotide inhibitors, an analysis of cardiac failure/cardiomyopathy events was performed. No cardiac failure/cardiomyopathy AEs were reported.

Cardiac Arrhythmias/Bradycardia: A subject experienced a Grade 1 AE of bradycardia on Day 8, which resolved on posttreatment Day 168. The event was assessed as related to study drug and study drug was not interrupted. The subject was hospitalized for 1 day on Day 10 for an SAE of Grade 2 hypotension.

Adverse Events During the First 2 Weeks of Treatment for Subjects Using a Beta Blocker, a Calcium Channel Blocker, or Neither: No subject had on-treatment beta blocker or calcium channel blocker use. One subject without on-treatment beta blocker or calcium channel blocker use had a Grade 1 AE of dizziness during the first 2 weeks of treatment, and 1 subject had a Grade 1 AE of bradycardia.

Amiodarone Use: No subject received amiodarone during treatment with SOF/VEL/VOX.

## Other Adverse Events of Interest

There were no reports of other adverse events of interest defined as follows: dermatologic events (defined as events within the skin and subcutaneous tissue disorders SOC that were serious, Grade 3 or above, or resulted in discontinuation of SOF/VEL/VOX), pancytopenia (including aplastic anemia) events, psychiatric events relevant to suicide ideation or attempt, pancreatitis events, rhabdomyolysis/myopathy events, renal failure events, and hepatic events (serious hepatic failure events, hepatic AEs leading to discontinuation of SOF/VEL/VOX, or subjects requiring liver transplantation).

## Vital Signs, Physical Findings, and Other Observations Related to Safety

The effects of study treatment on development and growth were assessed by changes from baseline in Tanner pubertal stage, bone age assessments, height, weight, and BMI. No notable effects of Vosevi on development, growth or vital signs as assessed by changes from baseline through posttreatment Week 24, were observed.

## Tanner Pubertal Staging

Male

At baseline, the majority of male subjects were at Tanner stage 4 or 5 for pubic hair and genitalia development (75.0%, 6 of 8 subjects). At end of treatment and at posttreatment Weeks 12 and 24, no male subjects (8 subjects) had a decrease from baseline in their Tanner stage for pubic hair and genitalia development.

<div style=\"page-break-after: always\"></div>

## Female

At baseline, the majority of female subjects were at Tanner stage 4 or 5 for pubic hair and breast development (69.2%, 9 of 13 subjects). At end of treatment and at posttreatment Weeks 12 and 24, no female subjects (13 subjects) had a decrease from baseline in their Tanner stage for pubic hair and breast development.

## Height, Weight, and Body Mass Index

## Height

The median (Q1, Q3) body height at baseline was 162.0 (158.0, 166.0) cm. At posttreatment Week 24, the median (Q1, Q3) change from baseline in body height was 1.8 (0.8, 3.0) cm. The median (Q1, Q3) body height percentile at baseline was 47.9 (32.4, 63.2). At posttreatment Week 24, the median (Q1, Q3) change in body height percentile was -0.2 (-3.1 , 4.3). This minor negative change in body height percentile was not considered clinically relevant and could reflect variability in how height was assessed.

## Weight

The median (Q1, Q3) body weight at baseline was 54.2 (46.1, 57.8) kg. At posttreatment Week 24, the median (Q1, Q3) change from baseline in body weight was 2.7 (1.0, 3.5) kg. The median (Q1, Q3) body weight percentile at baseline was 54.0 (30.9, 75.9). At posttreatment Week 24, the median (Q1, Q3) change in body weight percenti le was -1.6 (-5.2, 4.3).

## Body Mass Index

The median (Q1, Q3) BMI at baseline was 19.8 (18.5, 22.0) kg/m2. At posttreatment Week 24, the median (Q1, Q3) change from baseline in BMI was 0.2 (-0.2, 0.8) kg/m 2. The median (Q1, Q3) BMI percentile at baseline was 57.4 (30.2, 73.6). At posttreatment Week 12, the median (Q1, Q3) change in BMI percentile was -2.8 (-7.1, 2.5).

## Bone Age Assessments

## Radiographic Bone Age Assessments

The median (Q1, Q3) radiographic bone age at baseline was 14.5 (13.7, 16.0) years. At end of treatment (Week 8), the median (Q1, Q3) change from baseline was 0.0 (0.0, 0.5) years.

## Bone Age Biomarkers

The median (Q1, Q3) CTX at baseline was 1.35 (1.05, 2.35) ng/mL. At posttreatment Week 24, the median (Q1, Q3) change from baseline was -0.22 (-0.55, -0.04) ng/mL, and was not considered clinically relevant.

The median (Q1, Q3) P1NP at baseline was 383.25 (175.00, 944.20) ng/mL. At posttreatment Week 24, the median (Q1, Q3) change from baseline was 101.50 (-359.00, -24.98) ng/mL, and was not considered clinically relevant.

## Vital Signs

No notable changes from baseline in vital signs (temperature, pulse, respiration, systolic blood pressure, or diastolic blood pressure) were observed during the study.

<div style=\"page-break-after: always\"></div>

## Pregnancies

No pregnancies were reported during this study.

## Serious adverse event/deaths/other significant events

## Serious Adverse Events

One subject had a Grade 2 SAE of hypotension on Day 10, which was assessed as related to study drug and resolved the same day. Study drug was not interrupted. No relevant medical history or concomitant medication use was reported. This subject experienced multiple AEs of mostly Grade 1 nausea, drowsiness, diarrhea, and dyspnea with a duration of 1 day beginning on Day 1 through Day 46. The subject experienced a Grade 2 AE of abdominal pain with unknown start and end dates during the first month of treatment as well as a Grade 1 AE of dizziness after Day 46 with unknown start and end dates. No medications were administered for any of these events. Most of the AEs were assessed as related to study drug, and study drug dosing was not changed. This subject also experienced an AE of Grade 1 bradycardia that started on Day 8 and resolved Day 224.

## Deaths

No deaths were reported during this study.

## Laboratory findings

Overall, 28.6% of subjects (6 of 21) had a Grade 1 laboratory abnormality, no subjects had Grade 2 or 3 laboratory abnormalities, and 4.8% of subjects (1 of 21) had a Grade 4 laboratory abnormality.

Laboratory findings do not indicate a different safety profile compared to adults. Overall, ALT and AST decreased with the duration of treatment and no change from baseline in bilirubin was observed.

## Haematology

No Grade 3 or 4 haematologic laboratory abnormalities were reported during the study. No subject experienced a postbaseline haemoglobin value &lt; 10 g/dL or &lt; 8.5 g/dL. No clinically meaningful changes from baseline in neutrophils, lymphocytes, haemoglobin or platelets were observed .

## Chemistry

An isolated Grade 4 increase in potassium (hyperkalemia) was reported for 1 subject (4.8%) at Week 1. The subject had no relevant medical history and was asymptomatic, and the value was within normal limits on repeat testing.

## On-Treatment Liver-Related Abnormalities

No subject met any of the criteria for on-treatment liver-related laboratory abnormalities. The 3 liverrelated laboratory criteria assessed were as follows:

- AST or ALT &gt; 3 x ULN and total bilirubin &gt; 2 x ULN
- ALT &gt; 5 x ULN
- Total bilirubin &gt; 2 x ULN

<div style=\"page-break-after: always\"></div>

## Total Bilirubin

No Grade 3 or 4 elevations in total bilirubin were reported and no notable changes from baseline in total bilirubin were observed.

## Alanine Aminotransferase

No graded ALT laboratory abnormalities were reported during this study. Coincident with suppression of viral replication, all subjects had ALT normalization by Week 4. During treatment, median changes from baseline ranged from -10 to -14 U/L.

## Aspartate Aminotransferase

No Grade 3 or 4 AST elevations were reported during this study. Laboratory results for AST were similar to those for ALT. Coincident with suppression of viral replication, median AST decreased from baseline for the duration of the treatment period and at the posttreatment Week 4 visit.

## Safety in special populations

Not applicable.

## Safety related to drug-drug interactions and other interactions

As the drug interaction profile of SOF/VEL/VOX in subjects 12 to &lt; 18 years old is not expected to differ from that in adult subjects, no additional drug interaction studies of SOF/VEL/VOX were conducted for subjects 12 to &lt; 18 years old. No new findings relevant to the coadministration of SOF/VEL/VOX with other drugs are submitted with this update to the marketing application. From a clinical perspective, this application raised no new safety issues regarding interactions.

## Discontinuation due to adverse events

No subject had an AE that led to premature discontinuation or interruption of study drug.

## Post marketing experience

No post marketing data were submitted with this application. Any off-label use of SOF/VEL/VOX in patients 12 to &lt; 18 years old and any associated trends are routinely monitored by the MAH and documented in the PSURs.

## 2.6.1. Discussion on clinical safety

The Vosevi paediatric study was not powered to generate a comprehensive safety database in children and no control arm was available for comparison. This is considered acceptable since the main objective of the study is to provide PK data.

As exposure is comparable, safety can be extrapolated from the adult safety database through a PKbridge, in line with the EMA guidance. The CHMP also considered that eligible patients will enrol in a registry study GS-US-334-1113 for a total of up to 5 years for assessments of growth, quality of life, and long-term viral suppression (if applicable), as these issues are particular causes of concern in the paediatric population.

<div style=\"page-break-after: always\"></div>

From the limited safety dataset, there were no findings indicating a different safety profile compared to adults, which was considered reassuring by the CHMP.

Further to the request from the CHMP, the MAH amended the indication statement to 'patients aged 12 years and older and weighing at least 30 kg' to avoid patients below 30 kg being dosed with Vosevi (400 mg /100 mg /100 mg) and risk overexposure.

## 2.6.2. Conclusions on the clinical safety

The CHMP concluded that Vosevi is safe in the treatment of chronic HCV in adolescent patients 12 &lt; 18 years of age and weighing at least 30 kg.

## 2.7. Risk Management Plan

## Safety concerns

The summary of safety concerns as per RMP version 5 is provided below

| Important Identified Risks   | Severe bradycardia and heart block when used with concomitant amiodarone   |
|------------------------------|----------------------------------------------------------------------------|
|                              | HBV reactivation in HBV/HCV coinfected patients                            |
| Important Potential Risks    | Recurrence of HCC                                                          |
|                              | Emergence of HCC                                                           |
| Missing Information          | Safety in pregnant women                                                   |
|                              | Safety in patients with previous HCC                                       |
|                              | Safety in patients with moderate or severe hepatic impairment              |

## Pharmacovigilance plan

The following Table outlines the ongoing and planned additional pharmacovigilance activities in the RMP.

<div style=\"page-break-after: always\"></div>

TablePartIll.3. OngoingandPlannedAdditionalPharmacovigilanceActivities

| Study Status                                                                                                                                                                                                | SummaryofObjectives                                                                                                                                                                                         | Safety Concerns                                                                                                                                                                                             | Milestones                                                                                                                                                                                                  | Due dates                                                                                                                                                                                                   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 1 -Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                   | Category 1 -Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                   | Category 1 -Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                   | Category 1 -Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                   | Category 1 -Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization                                                                                   |
| DAA-PASS: A post-authorisation safety studyofearlyrecurrence of hepatocellular carcinoma in HCV-infected patients after direct-acting antiviral therapy                                                     | To evaluate the impact of DAA treatment on the incidence ofHCC recurrence,relative to no DAA therapy                                                                                                        | Importantpotential risk:Recurrence of HCC Missinginformation: Safety in patients with previous HCC                                                                                                          | Submission of final report                                                                                                                                                                                  | Final study report Q3 2021                                                                                                                                                                                  |
| Category 2-Imposedmandatory additional pharmacovigilance activitieswhich areSpecific Obligations inthe contextofa conditionalmarketingauthorization or amarketingauthorizationunderexceptionalcircumstances | Category 2-Imposedmandatory additional pharmacovigilance activitieswhich areSpecific Obligations inthe contextofa conditionalmarketingauthorization or amarketingauthorizationunderexceptionalcircumstances | Category 2-Imposedmandatory additional pharmacovigilance activitieswhich areSpecific Obligations inthe contextofa conditionalmarketingauthorization or amarketingauthorizationunderexceptionalcircumstances | Category 2-Imposedmandatory additional pharmacovigilance activitieswhich areSpecific Obligations inthe contextofa conditionalmarketingauthorization or amarketingauthorizationunderexceptionalcircumstances | Category 2-Imposedmandatory additional pharmacovigilance activitieswhich areSpecific Obligations inthe contextofa conditionalmarketingauthorization or amarketingauthorizationunderexceptionalcircumstances |
| None                                                                                                                                                                                                        | None                                                                                                                                                                                                        | None                                                                                                                                                                                                        | None                                                                                                                                                                                                        | None                                                                                                                                                                                                        |
| Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                     | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                     | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                     | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                     | Category3-Requiredadditionalpharmacovigilanceactivities                                                                                                                                                     |
| DeNovoDAAPASS:A study to evaluate therisk of denovohepatocellular carcinomainpatientswith compensated cirrhosis treated with direct acting antiviralsfor chronic hepatitis C                                | To evaluate among compensatedcirrhotic patients,whether DAA therapyfor chronicHCV infectionincreasestherisk ofincident HCC compared tonotreatmentortreatment withIFN-basedregimens                          | Importantpotential risk:Emergence of HCC                                                                                                                                                                    | Submission of updated joint protocol                                                                                                                                                                        | 02 April 2019                                                                                                                                                                                               |
| DeNovoDAAPASS:A study to evaluate therisk of denovohepatocellular carcinomainpatientswith compensated cirrhosis treated with direct acting antiviralsfor chronic hepatitis C                                | To evaluate among compensatedcirrhotic patients,whether DAA therapyfor chronicHCV infectionincreasestherisk ofincident HCC compared tonotreatmentortreatment withIFN-basedregimens                          | Importantpotential risk:Emergence of HCC                                                                                                                                                                    | EndofData Collection                                                                                                                                                                                        | 18months after protocol approval by IRB and PRAC                                                                                                                                                            |
| DeNovoDAAPASS:A study to evaluate therisk of denovohepatocellular carcinomainpatientswith compensated cirrhosis treated with direct acting antiviralsfor chronic hepatitis C                                | To evaluate among compensatedcirrhotic patients,whether DAA therapyfor chronicHCV infectionincreasestherisk ofincident HCC compared tonotreatmentortreatment withIFN-basedregimens                          | Importantpotential risk:Emergence of HCC                                                                                                                                                                    | Final Report                                                                                                                                                                                                | 12 months after end of data collection                                                                                                                                                                      |

## Risk minimisation measures

Routine risk minimisation activities proposed to manage the safety concerns of the medicinal product are provided in the table below.

<div style=\"page-break-after: always\"></div>

Table Part V.2. Summary Table ofPharmacovigilance andRiskMinimization

## Activities bySafety Concern

| Safety Concern                                                           | Risk Minimization Measures                                                                                                  | Pharmacovigilance Activities                                                                                                                                                                   |
|--------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risk(s)                                             | Important identified risk(s)                                                                                                | Important identified risk(s)                                                                                                                                                                   |
| Severe bradycardia and heart block when used with concomitant amiodarone | Routine risk minimization measures: SmPC section 4.4, 4.5, and 4.8 PL section 2. Additional riskminimization measures: None | Routine pharmacovigilance activitiesbeyond adversereactions reporting and signal detection: Targeted follow-up questionnaire for bradyarrhythmia Additional pharmacovigilance activities: None |
| HBVreactivation inHBV/HCV coinfected patients                            | Routine risk minimization measures: SmPC Section 4.4 PL Section 2 Additional risk minimization measures: None               | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                               |

<div style=\"page-break-after: always\"></div>

| Safety Concern              | Risk Minimization Measures                                                                                                                                                                                                                                                         | Pharmacovigilance Activities                                                                                                                                                                                                                                                                                                                                                                          |
|-----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important potential risk(s) | Important potential risk(s)                                                                                                                                                                                                                                                        | Important potential risk(s)                                                                                                                                                                                                                                                                                                                                                                           |
| Recurrence of HCC           | Routine risk minimization measures: None Additional risk minimization measures: None The need for risk minimization measures will be reassessed following the availability of the results from a study for HCC recurrence.                                                         | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study to assess the impact of DAA treatment on the incidence of HCC recurrence, relative to no DAA therapy                                                                                                                                                |
| Emergence of HCC            | Routine risk minimization measures: None Additional risk minimization measures: None The need for risk minimization measures will be reassessed following the availability of results from a study to investigate the impact of DAA therapies on the incidence and type of de novo | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study to evaluate the risk of de novo HCC in patients with compensated cirrhosis treated with DAAs for chronic hepatitis C                                                                                                                                |
| Missing information         | Missing information                                                                                                                                                                                                                                                                | Missing information                                                                                                                                                                                                                                                                                                                                                                                   |
| Safety in pregnant women    | Routine risk minimization measures SmPC section 4.6 PL section 2. Additional risk minimization measures: None                                                                                                                                                                      | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: Proactive follow-up to obtain information on maternal and patermal profile including medical history, risk factors, trimester and duration of exposure, and expected delivery date. Proactive follow-up on course and outcome of pregnancy and lactation. Additional pharmacovigilance activities: None |

<div style=\"page-break-after: always\"></div>

| Safety Concern                                                | Risk Minimization Measures                                                                                                                                                                                                 | Pharmacovigilance Activities                                                                                                                                                                                                                          |
|---------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Safety in patients with previous HCC                          | Routine risk minimization measures: None Additional risk minimization measures: None The need for risk minimization measures will be reassessed following the availability of the results from a study for HCC recurrence. | Routinepharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: Study to assess the impact of DAA treatment on the incidence of HCC recurrence, relative to no DAA therapy |
| Safety in patients with moderate or severe hepatic impairment | Routine risk minimization measures: SmPC Sections 4.2, 4.4 and 5.2 PL Section3 Additional risk minimization measures: None                                                                                                 | Routine pharmacovigilance activities beyond adverse reactions reporting and signal detection: None Additional pharmacovigilance activities: None                                                                                                      |

## Conclusion

The CHMP and PRAC considered that the risk management plan version 5.0 is acceptable.

## 2.8. Pharmacovigilance

## Periodic Safety Update Reports submission requirements

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.9. Product information

## 2.9.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable.

No full user consultation with target patient groups on the package leaflet has been performed on the basis of a bridging report making reference to Vosevi 400/100/100mg film-coated tablets. The bridging report submitted by the MAH has been found acceptable.

## 2.9.2. Additional monitoring

Pursuant to Article 23(1) of Regulation No (EU) 726/2004, Vosevi (sofosbuvir / velpatasvir / voxilaprevir) is included in the additional monitoring list as it had a PASS imposed at the time of

<div style=\"page-break-after: always\"></div>

authorisation.

Therefore, the summary of product characteristics and the package leaflet includes a statement that this medicinal product is subject to additional monitoring and that this will allow quick identification of new safety information. The statement is preceded by an inverted equilateral black triangle.

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

HCV infection has an estimated global prevalence of 1%, i.e. a total of 71 million individuals chronically infected with HCV. Although data on the global prevalence of HCV in children are limited, approximately 3.3 million children worldwide, aged 0 to 18 years, were estimated to be with viraemic HCV infection in 2018.

The natural history of chronic HCV infection in children is relatively benign. Most children are asymptomatic or have mild nonspecific symptoms; cirrhosis development within childhood/adolescence is rare but has been reported.

The HCV has significant genetic (RNA sequence) variability; 8 major genotypes have been identified: genotypes 1 and 3 are the most prevalent globally (46% and 30%, respectively) while genotypes 2, 4, and 6 represent approximately 23% of cases. Genotypes 5 and 7 comprise &lt; 1%, and genotype 8 has only recently been identified.

## 3.1.2. Available therapies and unmet medical need

HCV treatment for adults has been transformed by the development and approval of DAA agents, including sofosbuvir-based compounds. Despite the high sustained virologic response rates with DAAs in clinical studies, as well as real-world studies, there are patients who fail multi-DAA-based therapies.

Some of the DAAs have recently been approved for the treatment of adolescents and children. Although DAA failures in the paediatric population currently represent a small unmet medical need, this is anticipated to increase over time as DAA treatment in this population increases and retreatment options become limited for patients who fail DAA treatment. Vosevi would offer a treatment regimen for adolescents, regardless of genotype, prior treatment failure, or presence of compensated cirrhosis.

## 3.1.3. Main clinical studies

Study GS-US-367-1175 was an open-label study evaluating the PK, safety and antiviral activity of SOF/VEL/VOX in adolescent subjects with chronic HCV infection. A total of 21 subjects were enrolled and received SOF/VEL/VOX for 8 weeks (all subjects were DAA-naive without compensated cirrhosis). All 21 subjects completed study drug and were included in both the FAS and the Safety Analysis Set.

<div style=\"page-break-after: always\"></div>

## 3.2. Favourable effects

The favourable effects of Vosevi are well-known from the adult pivotal trials. In this paediatric application, the efficacy is established through a PK-bridge.

The proposed posology in adolescents regarding SOF and VEL has previously been approved (i.e. Epclusa). The popPK analysis supports the posology.

With regards to clinical outcomes, 21 of 21 patients 12 &lt;18 years of age achieved SVR12. No subject had virologic failure, there was no on-treatment breakthrough or relapse observed in subjects through posttreatment Week 12 or posttreatment Week 24. However, it is not evident that this outcome could not have been reached without voxilaprevir.

Vosevi is expected to be effective in the treatment of HCV in adolescents from 12 years of age and weighing at least 30 kg.

## 3.3. Uncertainties and limitations about favourable effects

The VOX popPK model was not deemed optimal. However, based on observed PK data for VOX, the exposure, including Cmin, was overlapping with the adult exposure. The MAH´s conclusion that the VOX exposures in adolescents are similar to those in non-cirrhotic adults, for which safety and efficacy have been established, was agreed by the CHMP.

Given that the pharmacologic targets of SOF/VEL/VOX are viral and not host-related, the PK-PD relation is expected to be unchanged without additional uncertainty being introduced in adolescents other than potential age-related differences in treatment adherence.

## 3.4. Unfavourable effects

The safety profile of Vosevi is well-established in adults and it is not expected to be substantially different in a paediatric setting. The limited paediatric safety dataset did not raise any age-specific issues. The treatment was well-tolerated and all reported AEs were mild to moderate (Grade 1 or Grade 2). One of 21 subjects experienced a Grade 2 SAE of hypotension assessed as related to study drug, which resolved the same day.

## 3.5. Uncertainties and limitations about unfavourable effects

This product contains three active substances: SOF, VEL and VOX. The simulated exposure for SOF and VEL showed slightly higher exposure in adolescents compared to adults. The proposed posology is the same as what has been previously deemed satisfactory in paediatric patients for combinations including SOF and VEL (Epclusa). The CHMP considered that the higher exposure of SOF and VEL does not raise concerns with regards to safety in paediatric patients weighing above 30 kg.

<div style=\"page-break-after: always\"></div>

## 3.6. Effects Table

| Favourable effects           | Favourable effects           | Favourable effects                            | Favourable effects                                       | Favourable effects                                | Favourable effects           |
|------------------------------|------------------------------|-----------------------------------------------|----------------------------------------------------------|---------------------------------------------------|------------------------------|
| SOF/VEL/VOX (400/100/100 mg) | SOF/VEL/VOX (400/100/100 mg) | SOF/VEL/VOX (400/100/100 mg)                  | SOF/VEL/VOX (400/100/100 mg)                             | SOF/VEL/VOX (400/100/100 mg)                      | SOF/VEL/VOX (400/100/100 mg) |
|                              |                              | Mean (%CV)                                    | Mean (%CV)                                               | %GMR(90% CI)                                      | Uncertainties / Strength of  |
| Analyte                      | PK Parameter                 | Adolescent Subjects ≥ 30 kg                   | Adult Phase 2/3 SOF/VEL/VOX Population                   | Adolescent Subjects vs Adult Phase 2/3 Population | evidence                     |
| SOF                          | AUC tau (h•ng/mL)            | 2474.8 (50.4)                                 | 1665.3 (30.1)                                            | 137.75 (123.66, 153.45)                           | Model predicted              |
| SOF                          | C max (ng/mL)                | 1304.7 (69.9)                                 | 677.9 (35.4)                                             | 162.64 (138.53, 190.94)                           | Model predicted              |
| GS- 331007                   | AUC tau (h•ng/mL)            | 14,890.2 (21.0)                               | 12,834.1 (29.0)                                          | 118.49 (107.02, 131.19)                           | Model predicted              |
| GS- 331007                   | C max (ng/mL)                | 1278.1 (16.1)                                 | 744.3 (28.3)                                             | 176.55 (158.98, 196.06)                           | Model predicted              |
| VEL                          | AUC tau (h•ng/mL)            | 6773.0 (35.0)                                 | 4041.1 (48.6)                                            | 176.53 (147.25, 211.63)                           | Model predicted              |
| VEL                          | C max (ng/mL)                | 621.8 (37.6)                                  | 311.1 (56.1)                                             | 215.54 (174.79, 265.80)                           | Model predicted              |
| VEL                          | C tau (ng/mL)                | 92.0 (49.6)                                   | 51.2 (64.7)                                              | 188.51 (154.18, 230.49)                           | Model predicted              |
| VOX                          |                              | Adolescent Subjects ≥ 30 kg median (min- max) | Adult Phase 2/3 SOF/VEL/VOX Population median (min- max) | Adolescent Subjects vs Adult Phase 2/3 - ratio    |                              |
| VOX                          | C 16-24h (ng/mL)             | 28.9 (6.0-126)                                | 31.8(2.2-1510)                                           | 0.91                                              | Observed                     |
| VOX                          | C 24-32h (ng/mL)             | 17.9(5.9-95.5)                                | 22.8(2.4-3440)                                           | 0.79                                              | Observed                     |

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The favourable effects of Vosevi in terms of sustained virologic response are well-known from the adult pivotal trials and can be extrapolated to adolescents.

Extrapolating from the safety profile in adults, the risks associated with Vosevi use are expected to be relatively mild also in adolescents.

## 3.7.2. Balance of benefits and risks

Given the natural course of chronic HCV infection, the high cure rate and the safety profile of Vosevi, the favourable effects are considered to outweigh the unfavourable effects.

<div style=\"page-break-after: always\"></div>

## 3.8. Conclusions

The overall B/R of Vosevi is positive.

## 4. Recommendations

## Outcome

Based on the CHMP review of data on quality and safety and efficacy, the CHMP considers by consensus that the benefit-risk balance of Vosevi 200/50/50 mg film-coated tablets is favourable in the following indication:

- Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg.

The CHMP therefore recommends the extension(s) of the marketing authorisation for Vosevi subject to the following conditions:

## Conditions or restrictions regarding supply and use

Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).

## Conditions and requirements of the marketing authorisation

## Periodic Safety Update Reports

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## Conditions or restrictions with regard to the safe and effective use of the medicinal product

## Risk Management Plan (RMP)

The MAH shall perform the required pharmacovigilance activities and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation and any agreed subsequent updates of the RMP.

An updated RMP should be submitted:

- At the request of the European Medicines Agency;
- Whenever the risk management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit/risk profile or as the result of an important (pharmacovigilance or risk minimisation) milestone being reached.

<div style=\"page-break-after: always\"></div>

## Obligation to conduct post-authorisation measures

The MAH shall complete, within the stated timeframe, the below measures:

| Description                                                                                                                                                                                                                                                                                                          | Due date   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|
| In order to evaluate the recurrence of hepatocellular carcinoma associated with Vosevi, the MAH shall conduct and submit the results of a prospective safety study using data deriving from a cohort of a well-defined group of patients, based on an agreed protocol. The final study report shall be submitted by: | Q3 2021    |

## Conditions or restrictions with regard to the safe and effective use of the medicinal product to be implemented by the Member States.

Not applicable.

These conditions fully reflect the advice received from the PRAC.

## Paediatric Data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan PIP P/0006/2020 and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

In addition, CHMP recommends the variation(s) to the terms of the marketing authorisation concerning the following change(s):

| Variations requested   | Variations requested                                                                                                           | Type    | Annexes affected     |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|----------------------|
| C.I.6.a                | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I, II, IIIA and IIIB |

Extension of indication to include paediatric use in patients aged 12 years and older and weighing at least 30 kg. Sections 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 5.0) is updated in accordance. Furthermore, the MAH took the opportunity to implement minor editorial updates in module 3.2.P and minor editorial updates throughout the Product Information, and to update the list of local representatives in the Package Leaflet.